

1 **Pontine pathology mediates common symptoms of**
2 **blast-induced chronic mild traumatic brain injury**

3 James S. Meabon^{1,2*}, Abigail G. Schindler^{2,3}, Daniel R. Murray¹, Elizabeth A. Colasurdo¹, Carl
4 L. Sikkema¹, Joshua W. Rodriguez¹, Mohamed Omer¹, Marcella M. Cline⁴, Aric F. Logsdon³,
5 Donna J. Cross⁵, Todd L. Richards⁶, Kole D. Meeker^{3,7}, Andrew Shutes-David^{1,3}, Mayumi Yagi³,
6 Daniel P. Perl⁸, Desiree A. Marshall⁹, C. Dirk Keene⁹, William A. Banks^{2,3,11}, Ronald G.
7 Thomas^{12,13}, Cory McEvoy¹⁴, Adam Crabtree¹⁴, Jake R. Powell¹⁵, Jason P. Mihalik¹⁵, Kathleen
8 F. Pagulayan^{1,16}, Murray A. Raskind^{1,2}, Elaine R. Peskind^{1,2}, & David G. Cook^{3,10,11}

9
10
11 ¹ VA Northwest Mental Illness Research, Education, and Clinical Center (MIRECC), VA
12 Puget Sound Health Care System (VA Puget Sound), Seattle, WA, USA.

13
14 ² Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle,
15 WA, USA.

16
17 ³ Geriatric Research, Education, and Clinical Center (GRECC), VA Puget Sound Health
18 Care System (VA Puget Sound), Seattle, WA, USA.

19
20 ⁴ Department of Molecular and Cellular Biology, University of Washington, Seattle, WA,
21 USA.

22
23 ⁵ Department of Radiology, University of Utah, Salt Lake City, UT, USA.

24
25 ⁶ Department of Radiology, University of Washington, Seattle, WA, USA.

26
27 ⁷ Immusoft, Seattle, WA, USA.

28
29 ⁸ Department of Pathology, DoD/USU Brain Tissue Repository and Neuropathology Core
30 Laboratory, Uniformed Services University, Bethesda, MD, USA.

31
32 ⁹ Department of Laboratory Medicine and Pathology, University of Washington, Seattle,
33 WA, USA.

34
35 ¹⁰ Department of Pharmacology, University of Washington, Seattle, WA, USA.

36
37 ¹¹ Department of Medicine, University of Washington, Seattle, WA, USA.

38
39 ¹² Alzheimer's Disease Cooperative Study, University of California San Diego, La Jolla,
40 CA, USA.

42 ¹³ Division of Biostatistics, Department of Family Medicine & Public Health, University of
43 California San Diego, La Jolla, CA, USA.

44

45 ¹⁴ United States Army Special Operations Command, Fort Bragg, NC, USA.

46

47 ¹⁵ Physical Therapy, Department of Allied Health Sciences, School of Medicine, University
48 of North Carolina, Chapel Hill, NC, USA.

49

50 ¹⁶ Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA.

51

52

53

54 * To whom correspondence should be addressed:

55

56 James S. Meabon, PhD

57 MIRECC, VA Puget Sound Health Care System

58 Department of Psychiatry and Behavioral Science

59 University of Washington School of Medicine

60 1660 S. Columbian Way

61 Seattle, WA 98108 USA

62

63 Phone: 206-277-4631

64 Email: james64@uw.edu

65

66 **Abstract**

67 Understanding how diffuse mild traumatic brain injuries can provoke common and persistent
68 post-concussive symptoms (PCS), such as impaired sleep, is crucial to prevent and treat chronic
69 disability and neurodegeneration. We mapped the spatially-resolved single cell landscape of
70 diffuse mTBI pathology in a mouse model of blast exposure; identifying brainstem injuries
71 predictive of later PCS. Repeated mTBI was necessary to establish chronic microglial activation
72 and phagocytosis of myelin in the pontine reticular formation; where IL33 release by
73 oligodendrocytes predicted microgliopathy. In postmortem brainstem tissues from patients with
74 traumatic brain injury, chronic microglial activation and myelin phagocytosis was evident up to
75 20 years after diffuse mTBI caused by blast. In living patients with chronic blast mTBI, myelin
76 injury in pontine projections mediated sleep disturbance and other PCS, with a dose dependent
77 effect of mTBI number on sleep disturbance severity. These results support a mechanism for
78 diffuse mTBIs to cause delayed persistent PCS.

79

80 Main

81 Mild traumatic brain injuries (mTBIs), or concussions, account for ~55 million annual global
82 TBI cases.¹ Although the causes of these injuries vary, persistent post-concussive symptoms
83 (PCS) following mTBI—e.g., development of impairments in concentration, memory, mood,
84 sensation, and sleep—are remarkably consistent.² This consistency suggests that mTBIs share a
85 common underlying neuropathology that may map to specific brain areas subserving these
86 functions (e.g., brainstem nuclei). However, the mechanisms underlying these deficits are poorly
87 understood, in part because mTBIs are undetectable on clinical neuroimaging.

88 Evidence suggests that TBIs may provoke the delayed development of deficits via
89 neuroimmune axes that regulate the microstructural repair of the nervous system.^{3,4} This means
90 that two critical determinants of long-term TBI outcomes are injury location and the subsequent
91 cellular response. An improved anatomical understanding of specific TBI pathologies under
92 conditions of diffuse injury, such as those caused by blast shock waves moving through the
93 brain, could help predict the development of generalized functional or behavioral deficits
94 following disease onset. Recent advances in high-dimensional spatially-resolved phenotyping
95 coupled with precise anatomical brain mapping may help us understand how changes in the
96 pathological microenvironment relate to persistent PCS following mTBI.

97 Even with minimal rotational head or body displacement, mTBI caused by exposure to
98 explosive overpressures transmits a rapid force throughout the brain, diffusely injuring its
99 tissues. The resulting pathology often differs from more kinetic forms of mTBI (e.g., caused by
100 falls, assaults, etc.);⁵ however, blast-mTBIs often cause persistent PCS that are indistinguishable
101 from other mTBIs.⁶⁻¹¹ Therefore, we examined mTBIs associated with blast overpressure
102 exposure in both military veterans and a mouse model of blast-mTBI with attenuated head

103 movement.¹² This approach avoids coup-contrecoup and “whiplash” injuries, while testing the
104 hypothesis that blast-mTBIs provoke conserved post-concussive symptoms mediated by chronic
105 pathological changes in brainstem nuclei.

106 **Results**

107 **Brainstem nuclei are vulnerable to mTBI**

108 Post-concussive symptoms typically relate to microscopic traumatic axonal injuries near small
109 blood vessels^{13,14} in specific anatomical regions, such as cerebellum and corpus callosum,¹³
110 where vessel lesions can drive circuit dysfunction.¹⁵ Functional injury of microvascular tight
111 junctions can be assessed by measuring the leakage of blood-borne molecules into the brain
112 parenchyma. This method paradoxically shows that after TBI, disruption of the blood-brain
113 barrier to the large molecule human albumin (66 kDa) is detectable prior to disruption to the
114 smaller molecule sucrose (342 Da). However, disruption to sucrose persists longer than
115 disruption to human albumin.¹⁶ We measured the functional integrity of the blood-brain barrier
116 across brain regions 15 minutes to 3 days after a single blast-mTBI using blood-borne ¹⁴C-
117 sucrose and ^{99m}Tc-Albumin. Although a non-significant accumulation of sucrose and albumin
118 was observed in the cortex during the acute phase (15 min after mTBI), significant leakages of
119 both large and small molecules were detected in the brainstem, but not cortex (**Fig. 1a**). This
120 indicates a regional vulnerability of the blood-brain barrier (BBB) to injury, with the brainstem’s
121 BBB being more susceptible to injury after a single mTBI than the cortex. Injured neurons in
122 areas of microvascular disruption can be identified by their uptake of blood-borne dyes that leak
123 into the brain across the disrupted BBB, whereas adjacent uninjured neurons remain unlabeled.¹⁷
124 We used this method to determine the relative frequency of injured neurons across brain regions

125 and white versus gray matter (**Fig. 1b, c**). Projection neurons, which are clearly distinguished
126 from glia using this method (**Fig. 1d, e**), were labeled by extravasated fluorescent dye and
127 occurred most frequently in the brainstem. In the brainstem, about 30% of mice showed evidence
128 of neuronal injury within one hour and up to 70% of mice had observable neuronal injury within
129 four hours of a single mTBI (**Fig. 1b**). Across sagittal brainstem sections, labeled cells occurred
130 most frequently in white matter (**Fig. 1c**). Blood-borne labeling of injured brainstem neurons was
131 visually more subtle than injured Purkinje cells of the inferior cerebellum (**Fig 1d**), a classic
132 injury pattern of mTBI,¹⁸ likely owing to their expansive and dense arborizations.

133 Injured brainstem neurons and areas of BBB damage coincided with local changes in
134 microglial morphology that are consistent with activation and phagocytosis of extravasated
135 materials (**Fig. 1d**). Diffuse axonal and neuronal injuries were primarily observed in the pontine
136 reticular formation (RF), one of several brainstem regions controlling sleep behavior (**Fig. 1e**).
137 Localized cellular injuries were observed laterally toward the brainstem surface, with frequent
138 prominent injuries along the ventral caudal surface, spinal trigeminal tract, and dorsal columns
139 and was independently identified by unguided investigators (AFL, KDM) blinded to the study
140 groups.

141 The development of brainstem tauopathy, indicating axon injury, paralleled increased
142 expression of aquaporin-4 (AQP4), which regulates the brain-wide convection of water. A
143 compensatory increase in the expression of magnesium superoxide dismutase (MnSOD), a
144 mitochondrial redox enzyme responsive to TBI-related cellular injury,¹² paralleled the increase in
145 the fluorescent labeling of injured neurons (**Fig. 1f**). Tauopathy in the pontine gray, medial
146 lemniscus, and RF persisted at least 24 hours after injury (**Fig. 1g, h**).

147 Cerebral edema often follows both clinical and experimental mTBI despite unremarkable
148 neuroimaging results. We postulated that the prominence of diffuse injury from the foramen
149 magnum to the 4th ventricle and the related changes in the AQP4 water transporter would be
150 accompanied by tissue swelling. Such swelling, we posited, would result in reduced 4th ventricle
151 volume per T2 MRI and be associated with secondary cerebral edema, yielding enlargement of
152 the 3rd and lateral cerebral ventricles. In group-blinded analyses of mice assessed 24 hours after a
153 single blast-mTBI, we found that mTBI induced significant enlargement of the lateral and 3rd
154 ventricular volume while reducing the 4th ventricular volume (**Fig. 1i, j**). These results indicate
155 that a single blast-mTBI can cause axonal injury and inflammation of the brainstem in the
156 absence of gross hemorrhage. Such injuries may contribute to more expansive secondary injuries
157 related to edema throughout the brain.¹⁹

158 **mTBI establishes persistent brainstem microgliopathy**

159 Repetitive mTBI is an environmental risk factor for chronic neurodegenerative phenotypes.²⁰⁻²²
160 Genetic risk factors for neurodegeneration often map to myeloid cells, including peripheral blood
161 monocytes and brain resident microglia.²³ However, our understanding of how disease-
162 associated immune phenotypes relate to TBI pathologies is incomplete. To determine the
163 relationship between myeloid phenotypes and the neuropathological landscape of the tissue
164 microenvironment after repeated mTBI, we first tested the *a priori* hypothesis that functional
165 alterations in brain myeloid cells would be a persisting and sensitive indicator of regional injury,
166 with the greatest changes occurring in the brainstem as seen during acute injury. To evaluate this
167 hypothesis, we used a RiboTag strategy to assess the active transcriptome specifically in brain
168 myeloid cells from mice with repeated TBI or sham exposure (1 per day for 3 days), avoiding the
169 trauma-induced changes in gene signatures evoked by *ex vivo* dissection of live tissue and cell

170 sorting that are known to occur.^{24,25} By using a tamoxifen-inducible CX3CR1-creER mouse line
171 shown to be superior in achieving brain macrophage specificity with the exclusion of neuron-
172 derived contaminating mRNA,²⁴ we employed a discovery approach followed by validation in an
173 additional secondary cohort to identify candidate genes differentially expressed across brainstem,
174 cerebellum, and cortical tissues in mice one month after repetitive mTBI (3x; 1 per day for 3
175 days), as compared with gene levels in tamoxifen-induced CX3CR1-creER control mice
176 receiving an equal number of sham-TBI treatments (**Fig. 2a, b, c**). Brainstem tissues showed
177 more differentially expressed myeloid genes than cerebellar or cortical tissues consistent with
178 acute injury patterns being concentrated in the brainstem.

179 We then performed gene ontology (GO) term analysis. Given that significantly fewer
180 genes were confirmed in the cortex and cerebellum, only differentially expressed genes
181 confirmed in brainstem tissue were used (**Fig. 2d**). In agreement with previous reports, blast-
182 mTBI-induced geneset enrichments in brainstem myeloid cells included programs for
183 macromolecular binding (e.g., *APOE*), lytic vacuole (e.g., *CD68*), exosome, cell adhesion and
184 locomotion.²³

185 Given that microglial properties shift in response to the conditions of their tissue
186 microenvironments, we developed an imaging mass cytometry (IMC) workflow to visualize how
187 the relations between microglial phenotypes and their tissue microenvironments changed in
188 response to TBI (**Fig. 2e**). To do this, we developed a panel of 35 metal-labeled antibodies
189 specific to murine TBI histology, including cellular, pathological, and signaling markers (**Table**
190 **S2**). Antibody-stained tissue slides were then laser-ablated and the subsequent signal was
191 detected with time-of-flight mass spectrometry, producing a 2-dimensional, rasterized

192 representation of metal abundances analogous to a highly-multiplexed microscope image.
193 Following *in silico* image segmentation into single cells in CellProfiler, analyses were conducted
194 in HistoCAT and R. We identified 256,295 cells from images of 8 coronal pontine hemisections
195 that were taken from randomly selected study mice and that provide tissue representation of
196 ventral pontine and dorsal structures near the 4th ventricle (**Fig. 2e**).

197 Phenotyping based on nonlinear dimensionality reduction was implemented using
198 Barnes-Hut t-distributed stochastic neighbor embedding (t-SNE) (**Fig. 2f; Fig. S1**). To define the
199 prominent microenvironmental phenotypes of single cells in the injured brain, we used unbiased
200 phenograph-based clustering to yield 36 distinct clusters for further analysis (**Fig. 2g**). This
201 method differentiated both unreactive microglia (cluster 4; Iba⁺, CCR2⁻, CD68^{lo}, ApoE^{lo}) and a
202 disease-associated microglial (DAM) phenotype (cluster 26; Iba⁺, CCR2⁻, CD63⁺, CD68^{hi},
203 ApoE^{hi}) consistent with single-cell RNA sequencing analyses of Alzheimer's disease brain and
204 neurodegenerative models,^{23,26,27} in addition to several non-microglial phenotypes representing
205 neuronal, vascular, glial, and peripheral immune cells. Intercellular associations, as measured by
206 neighborhood analysis, increased between spatially resolved disease-associated microglia with
207 IL33⁺ myelin (clusters 6 and 17), NeuN⁺ neurons (cluster 13) and HTT⁺ neurons (cluster 24) in
208 brain-injured mice whereas similar associations did not change in control mice (**Fig. 2h**). Taken
209 together, these findings suggest that repetitive mTBI provokes a persisting pontine
210 microgliopathy that is associated with slowly resolving neuronal and IL33⁺ myelin injury, which
211 can be spatially resolved and quantified using unbiased computational means.

212

213 **Myelin injury precedes sleep deficits**

214 Delayed-onset PCS are thought to reflect progressive changes in cellular phenotypes prior to
215 functional and structural brain changes. We used a data-driven approach to agnostically identify
216 specific regions of persisting brainstem pathology that could cause persistent PCS. More
217 specifically, we gated on disease-associated microglia in IMC images and measured their
218 average frequency distributions (i.e., DAM/total microglia) per subject across exclusive brain-
219 region image masks of whole pontine hemisections. We then used the results to inform later
220 hypothesis testing on the relations between pathology, chronic symptoms, and the known
221 functions of the brain regions. Representative IMC images of pontine disease-associated
222 microglia in blast-mTBI and sham control mice are shown in **Figure 3a**. TBI increased the
223 frequencies of disease-associated microglia in several areas with post-hoc FDR-adjusted analyses
224 identifying notable increases in the reticular formation (rf; $t[62]=3.366$, $q=0.0019$), spinal
225 trigeminal nerve tract (spn; $t[62]=3.066$, $q=0.0034$), ventral white matter (vwm; $t[62]=3.317$,
226 $q=0.0019$), and ventral cochlear nucleus (vco; $t[62]=6.448$, $q<0.0001$) (**Fig. 3b**). Since blast-
227 mTBI induces the association of DAM with myelin expressing the alarmin molecule IL33 (**Fig.**
228 **2i**), we examined the expression of IL33 among all 44,023 spatially resolved single
229 CNPase⁺/IL33⁺ oligodendrocytes distributed across these regions. Post-mTBI oligodendrocytes
230 of several pontine regions showed significant loss of the alarmin IL33 (vii: $t[42]=1.98$, $q=0.05$;
231 rf: $t[42]=3.225$, $q=0.0062$; in: $t[42]=3.406$, $q=0.0062$; spv: $t[42]=3.108$, $q=0.0062$; spn:
232 $t[42]=2.782$, $q=0.0118$; pyr: $t[42]=2.3$, $q=0.0278$; pcg: $t[42]=2.711$, $q=0.0118$; **Fig. 3c**), through
233 its apparent release from nuclear stores into the surrounding microenvironment (**Fig. 3d**).
234 Microglia, which express IL33R mRNA (**Fig. 3e**), accumulate in a predictive linear manner
235 driven by IL33 levels (**Fig. 3f**).

236 Next, we used a false-discovery rate-adjusted method to focus our analysis on the pontine
237 structure(s) displaying the most consistently altered IL33 expression following TBI. We found
238 highly significant mean IL33 reductions per oligodendrocyte for each blast and sham mouse in
239 the RF indicating robust and persisting white matter injury (**Fig. 3g**). Disease-associated
240 microglia heavily express the lytic vacuole protein CD68, which is known to facilitate
241 phagocytotic clearance of diseased tissue, including myelin.^{17,28} CNPase is an integral myelin
242 protein required for axon paranode maintenance²⁹ in that its axoglial decoupling is associated
243 with progressive axonal degeneration³⁰ and phagocytosis by microglia during dysmyelination²⁹
244 and Wallerian degeneration.³¹ Because IMC is limited to 2D analyses, we used 3D confocal
245 microscopy of sagittal brainstem sections near midline to measure how microglial internalization
246 of CNPase relates to both injury location across brainstem structures and the number of blast-
247 mTBIs administered. Phagocytosis of CNPase by both single-cell and clustered microglia was
248 observed in pons and medulla, with greater apparent co-localization observed in microglial
249 nodules than single microglia (**Fig. 3h, arrowheads**). One month after single or repeated (3x)
250 blast-mTBI, myelin consumption was measured as the number of CNPase-positive voxels inside
251 Iba-1-stained microglial volumes. Myelin consumption by microglia increased in relation to the
252 number of mTBIs ($F(2,85)=7.88$, $p=0.0007$) and anatomical location ($F(2,85)=4.536$,
253 $p=0.0134$)(**Fig. 3i**), with Tukey's post-hoc analyses determining these effects were driven by
254 repeated blast-mTBI (sham vs 1x.: 444 mean dif. (-5150 to 6037, 95%CI), $q=ns$; sham vs. 3x: -
255 8336 mean dif. (-13961 to -2711, 95%CI), $q=0.0019$).

256 Sleep impairment following TBI occurs in 30–65% of those with persistent PCS.^{32,33}
257 Interestingly, insomnia, which is characterized by difficulty initiating and maintaining sleep, is
258 more common with less severe TBIs and blast-related mTBIs.³⁴⁻³⁶ To measure changes in post-

259 traumatic sleep that are caused by blast-mTBI and that may contribute to the development of
260 later sleep impairment, we used a noninvasive sleep monitoring system to record changes in the
261 stereotypical sleep patterns of mice.^{37,38} When measured seven days after blast-mTBI, the sleep
262 bout duration and diurnal sleep-to-wake ratio of blast-mTBI mice was normal compared to sham
263 control mice (**Fig. 3j, k**) and was consistent with previous reports of TBI mice one week after
264 injury.³⁹ However, following a three-month period of recovery from repeated blast-mTBI,
265 injured mice developed a statistically significant increase in sleep fragmentation characterized by
266 a reduced average sleep bout duration and lower diurnal sleep:wake ratio (**Fig. 3j, k**) that was
267 similar to clinical insomnia in humans. Thus, the development of sleep impairment occurs after
268 the onset of microglial-associated pontine myelinopathy.

269

270 **Myelin injury mediates sleep injury**

271 We hypothesized a similar pathology would exist in the brainstem of military veterans with
272 blast-mTBI. In a neuropathological analysis of autopsy subjects with (n=4) and without (n=4)
273 blast-mTBI, phagocytic microglial nodules that highly express CD68 (i.e., microgliopathy; **Fig.**
274 **4a**) were often seen with internalized myelin (i.e., CNPase; **Fig. 4b**). Microglia nodules were
275 identified in the brainstem and cerebellar white matter tracts of subjects up to 20 years after their
276 last reported TBI. By observing IMC images stained with 6 antibodies specific for human protein
277 targets, we confirmed that human microglial nodules were phagocytic and transcriptionally
278 active (i.e., CD68⁺, negative for histone 3 lysine 27 trimethylation) in contrast to the adjacent,
279 uninvolved, normal-appearing microglia (**Fig. 4c**).

280 Insidious myelinopathy mediates several clinical diseases including multiple sclerosis,
281 Parkinson's disease, and stroke and may contribute to the earliest occurring changes in age-

282 related cognitive decline and disability following TBI.⁴⁰ Our findings in mice indicate that
283 diffuse axonal injury in the brainstem initiates latent white matter pathology that may drive the
284 development of a spectrum of delayed-onset behavioral impairments related to mTBI. Diverse
285 cognitive, behavioral, and somatic PCS occur in 77–97% of persons with repetitive TBI.^{35,41}
286 These persistent PCS develop over hours to months following injury⁴² and may become chronic,
287 lasting years.⁴³

288 To determine whether brainstem white matter changes caused by diffuse axonal injury
289 are associated with neurobehavioral symptoms in humans with blast-mTBI, we used magnetic
290 resonance diffusion tensor imaging tractography (DTI) in living US veterans with repetitive
291 blast-mTBI (n=20) and veterans deployed to the Iraq/Afghanistan war zones with no lifetime
292 history of TBI (n=19). Subject demographics are provided in **Supplemental Table 3**. Guided by
293 our animal model (**Fig. 3**), we reconstructed fiber tracts using the entire human pons as the seed
294 region to avoid placement bias or error (**Fig. 4d**). Consistent with our observation of TBI-related
295 myelin and neuronal injury in the pons of mice, TBI was associated with significant myelin
296 injury of pontine fibers in veterans with mTBI via measures of DTI fractional, axial, and radial
297 anisotropy (**Fig. 4e-g**). We next evaluated a possible dose-response between the number of blast-
298 mTBIs and changes in pontine fractional anisotropy (FA) while controlling for the potential
299 confounding variables of age and posttraumatic stress disorder (PTSD) symptom severity.
300 Reductions in adjusted pons FA were associated with increasing numbers of self-reported blast-
301 mTBIs (linear regression, $p < 0.0001$; **Fig. 4h**).

302 Diverse functions are controlled by highly conserved brainstem circuits, including
303 functions related to the common symptoms following mTBI: sleep structure, emotional state, and
304 sensorimotor integration. To learn whether the development of these symptoms may be mediated

305 by changes in pontine white matter, we first evaluated the linear relation between age- and PTSD
306 symptom severity-adjusted changes in pontine FA in all subjects and self-reported severity of
307 persistent PCS related to mTBI as measured by the total score on an augmented Neurobehavioral
308 Symptom Inventory (NSI+) questionnaire. Subjects rated symptom severities for dizziness,
309 imbalance, dyscoordination; headache, nausea, vision, sensitivity to light; hearing, ringing in the
310 ears, sensitivity to noise; numbness/tingling, changes in taste/smell; changes in appetite; changes
311 in concentration, forgetfulness, decision-making difficulty, slowed thinking; fatigue, sleep
312 impairment; anxiety, depression; irritability, poor frustration tolerance, getting into fights,
313 disinhibition, mood swings; apathy/withdrawal; and slowness in speech ranging from 0 to 4 (not
314 present, mild, moderate, moderately severe, severe) and symptom scores were summed (NSI+
315 total score). Using linear regression modeling, the relationship was highly significant
316 ($p < 0.0001$), indicating that greater total persistent PCS burden was associated with greater
317 reductions in pontine FA (**Fig. 4i**). The number of lifetime mTBIs ($\log_{10}(x+1)$ transformed)
318 similarly correlated with age- and PTSD symptom severity-adjusted measures of NSI+ total
319 score (Spearman's $r = 0.630$, 0.5024 to 0.7308 95% CI; $p = 2.7 \times 10^{-14}$) indicating that total
320 persistent PCS burden increases with the number of repeated mTBIs caused by blast exposure.

321 Lastly, we used statistical mediation analysis to evaluate the potential causal relationship
322 between pontine white matter injury and persistent PCS burden. Using both pontine FA and
323 NSI+ total scores adjusted for age and PTSD symptom severity, the regression coefficient
324 between the number of blast-mTBIs and persistent PCS burden (i.e., the direct effect, DE) and
325 the regression coefficient between pontine FA values and symptom burden were both significant
326 (**Fig. 4j; Fig. S6a**). The indirect effect was $(-0.006) * (-2715.00) = 16.3$ ($p < 0.01$). A validation
327 analysis using nonparametric bootstrapping procedures determined that the effect size 95%

328 confidence interval ranged from 9.460 to 23.05 (**Fig. 4k**). The validated adjusted causal
329 mediation was statistically significant ($p=2 \times 10^{-16}$), supporting the conclusion that diverse
330 persistent PCS following repetitive blast-mTBI are at least partially caused by pontine myelin
331 injury. An identical mediation analysis determined a statistically significant relation between
332 pontine FA and sleep impairment as measured by the Pittsburgh Sleep Quality Index (PSQI) total
333 score similarly adjusted for age and PTSD symptom severity. Using a bootstrap-validated
334 mediation analysis, both the adjusted causal mediation effect (ACME) and total effect (TE) were
335 significant (ACME: 3.2 (1.991 - 4.75, 95% CI; $p<0.0001$); TE: 3.866 (2.254 - 5.56, 95% CI;
336 $p<0.0001$)) (**Fig. 4l**). Taken together these results support the conclusion that chronic pontine
337 myelin injury drives diverse persistent PCS following repeated blast-mTBI.

338

339

340 **Discussion**

341
342 We showed that brainstem nuclei are vulnerable to a single diffuse blast-mTBI. Within 15
343 minutes, we observed significant and consistent entry of blood-borne molecules into the
344 brainstem parenchyma and highly variable entry into the cortex. One hour after mTBI, nearly
345 30% of experimental animals showed neuronal injury, seen as uptake of extravasated blood-
346 borne dyes into axonal projections and cell bodies, whereas <5% of mice showed similar cellular
347 injuries in the cortex. By four hours post-injury, nearly 50% of blast-mTBI mice showed cortical
348 neuronal injuries. This suggests that a therapeutic window to prevent widespread cortical
349 dissemination may exist in the initial 1 to 4 hours following blast-mTBI. Supported mechanisms
350 include subtle neuroinflammatory processes that are likely critical determinants of brain-wide
351 secondary injury, such as swelling of the brain. Such swelling develops within 14 days, is
352 typically seen as significant ventricular enlargement, and is often mistaken for hydrocephalus.⁴⁶
353 However, when single mTBI-injured rodents are allowed to recover for a month, we found no
354 overt microgliopathy or myelinopathy (**Fig. 3i**); this suggests that repeated injury is the key
355 driver of these phenotypes.

356 The way in which repeated TBIs provoke the development of chronic pathology and
357 persistent PCS is not well understood. We tested whether repeated diffuse mTBI causes the
358 progressive disruption of brainstem structures responsible for changes in arousal and sensation.
359 Using a data-driven approach, we agnostically identified injured areas by surveying the
360 distribution of spatially-resolved, disease-associated microglial phenotypes across pontine nuclei.
361 As expected, we observed that disease-associated microglia respond to neuronal and myelin
362 injuries following the acute-injury patterns marked by microvascular extravasation and diffuse
363 axon injury. We discovered, however, that release of oligodendroglial nuclear IL33 predicts the

364 regional density of disease-associated microglia, which can appear as single cells and small
365 clusters, or “nodules”, previously reported to facilitate the removal of degenerating axons and
366 myelin.^{31,47} Persisting pathologies of the pontine RF, first identified in our mouse model, were
367 subsequently verified in living veterans with repeated blast-mTBI and in neuropathological
368 studies in veterans with blast-mTBI from four independent laboratories.

369 We observed several highly stereotypical injury patterns to specific pontine nuclei
370 following repeated blast-mTBI. Among these, a key brainstem area critical for good sleep
371 hygiene is the pontine reticular formation. In living veterans with chronic repetitive blast-mTBI,
372 the myelin integrity of the combined rostral and cerebellar pontine projections that were
373 reconstructed by DTI tractography, were significantly correlated with the severity of persistent
374 PCS including sleep impairment. Projections of the ascending RF strongly innervate central
375 thalamic neurons^{48,49} that modulate the depolarization and firing of neocortical circuits through
376 input to the anterior forebrain mesocircuit and frontoparietal network.⁵⁰ These projections
377 thereby affect the organization of goal-directed behaviors⁵⁰ and modulate arousal levels affecting
378 cognition, stress, and sleep.^{48,51,52} Likewise, the pontine projections to the cerebellum integrate
379 cerebellar function with diverse brainstem nuclei, including most raphé nuclei, the locus
380 coeruleus, the pedunclopontine nucleus, and several segments of the RF.⁵³ Although lesions and
381 DTI abnormalities of the SCP have been frequently reported across a variety of TBI mechanisms
382 of injury and severity of TBI,^{17,54,55} their role in the development of persistent PCS remains
383 unknown. What is known is that experimental lesions of the SCP in cats result in nightly sleep
384 loss,⁵⁶ whereas cerebellectomized cats display increased drowsiness without sleep loss;⁵⁷ this
385 suggests that the prominent cerebellar injuries caused by TBI may also be a significant source of
386 sleep morbidity. Lastly, in keeping with our hypothesis that pontine myelin injury is a causal

387 mediator of persistent PCS, as opposed to the injury of specific output tracts which were not
388 declared *a priori*, we did not evaluate the individual contributions of rostral versus cerebellar
389 projections. Subsequent study is needed to determine the relative contributions of TBI-induced
390 injuries to the SCP versus the pontothalamic projections in the development of persistent PCS,
391 since each may pose unique diagnostic and interventional opportunities. Taken together, the
392 results of this study indicate that diffuse traumatic brain injuries caused by blast overpressures
393 may provoke common, though diverse, neurobehavioral symptoms caused by chronic pontine
394 white matter injuries in nuclei subserving their function.

395

396 **Methods**

397 **Study Design**

398 The aim of this study was to determine the frequency and pattern of diffuse axonal and white
399 matter injury in the brainstem following blast-mTBI and to evaluate its relationship with
400 common persistent PCS in both a mouse model of diffuse blast-mTBI with attenuated head
401 movement and in military veterans with history of blast mTBI. Blast exposures occur from all
402 directions, and may not be accompanied by any focal blunt force trauma. This study in a military
403 veteran cohort with primarily repetitive blast-mTBI enabled us to examine the effect of repetitive
404 diffuse blast mTBI on the relationship between brainstem structure and persistent PCS that may
405 be generalizable across mTBI without the confounds associated with excessive head movement,
406 which is well established to injure brainstem centers following TBI caused by diverse forms of
407 trauma.

408 A total of 39 male veterans reporting from 0 to 102 blast-induced mTBIs were studied.

409 Although female veterans were eligible for study inclusion, none enrolled. Study inclusion

410 criteria included documented military service in Iraq and/or Afghanistan with the US Armed
411 Forces during Operations Enduring Freedom, Iraqi Freedom, and/or New Dawn. Veterans
412 meeting VA/Department of Defense/American Congress of Rehabilitation Medicine criteria for
413 mTBI following at least one blast exposure were included in the TBI group.

414 Exclusion criteria for the study included a history of moderate to severe TBI, seizure
415 disorder, insulin-dependent diabetes, DSM-IV diagnosis of alcohol or other substance use
416 disorder, dementia, bipolar affective disorder, and psychotic disorders. Subjects using
417 medications likely to affect cognitive or behavioral assessments, such as opiates,
418 benzodiazepines, and sedating antihistamines, were also excluded. MRIs were contraindicated
419 for veterans with retained shrapnel or other metal objects, who were thus excluded from MRI.

420 A total of 232 male wild-type C57BL/6J, 20 Cx3cr1^{EGFP}/CCR2^{RFP} and 15
421 Cx3cr1tm2.1^{cre/ERT2}/ Rpl22tm1.1^{Psam/J} mice age 3 to 6 months were studied. Mice were randomly
422 assigned to either TBI or sham control groups. Group sizes were based on pathology in this and
423 other established TBI models.^{17,58-60} In each experiment, mice from the control and TBI groups
424 were analyzed under identical conditions.

425

426 **Human subjects**

427 Human studies were approved by the VA Puget Sound Health Care System Institutional Review
428 Board. All living veteran participants provided written informed consent prior to any study
429 procedures. The study conformed to institutional regulatory guidelines and principles of human
430 subject protections in the Declaration of Helsinki. Veterans with and without mild TBI were
431 characterized by physical, neurological, and behavioral examinations that included assessments
432 for PTSD using the PTSD Checklist-Military version total score, for sleep disturbance using the

433 PSQI total score, and for current post-concussive symptoms using the Likert-scaled NSI+
434 symptom questionnaire. The NSI+, based on the standard NSI, is a self-report instrument
435 consisting of the base 22 NSI questions plus the following six TBI-associated PCS: 1)
436 disinhibition, 2) apathy/withdrawal, 3) ringing in the ears, 4) mood swings, 5) getting into fights,
437 and 6) slowness in speech. Responses are scored on scale of 0-4; (0) None, (1) Mild, (2)
438 Moderate, (3) Severe, and (4) Very Severe. The Structured Clinical Interview for DSM-IV was
439 used to establish diagnoses of Axis I psychiatric disorders. A lifetime history of TBI was
440 obtained using a semi-structured TBI interview performed by two expert TBI clinicians
441 simultaneously.⁶¹ Magnetic resonance DTI was performed within 3 months of clinical
442 evaluation.

443

444 **Clinical neuropathology**

445 Human donor research brain specimens and their related clinical/exposure information were
446 collected and used as de-identified materials in accordance with procedures approved, as
447 appropriate, by the VA Puget Sound Health Care System, University of Washington, and the
448 Uniformed Services University Institutional Review Boards. Tissue samples were obtained from
449 brains donated, with informed consent by their legal next of kin, of veterans with a history of
450 mTBI caused by blast exposure and control subjects matched by age and sex but without a
451 lifetime history of TBI. Formalin fixed paraffin embedded (FFPE)-brain sections were de-
452 paraffinized and rehydrated using previously described procedures,¹⁷ blocked in 10% normal
453 goat serum (1 hour at room temperature), and stained overnight at 4°C using the following
454 antibodies: rabbit polyclonal anti-GFAP (Abcam, Burlingame, CA; 1:1,000), mouse monoclonal
455 anti-Iba-1 (Wako Chemicals, Richmond, VA; 1:1,000), or mouse anti-CD68 (Agilent, Santa

456 Clara, CA; 1:100). Heat-mediated antigen retrieval was performed in citrate buffer (pH 8.0;
457 80°C) for 30 minutes and then cooled to room temperature before further use. Stained slides
458 were mounted with ProLong Diamond antifade mountant (ThermoFisher Sci, Waltham, MA).

459

460 **Diffusion Tensor Imaging (DTI)**

461 Magnetic resonance DTI was performed using an established protocol^{17,61} on a 3.0 T Philips
462 Achieva whole-body scanner (Philips Medical Systems, Best, Netherlands) equipped with a 32-
463 channel radiofrequency head coil. Briefly, images were acquired using a single-shot spin-echo
464 echo-planar sequence with TR=10.76 sec; TE=93.5 msec; flip angle=80 degrees; matrix
465 size=128•128; field-of-view (FOV)=256•256; slice thickness=2mm; 64 gradient directions; and
466 b-factors=0 and 3,000s/mm².

467 Images were preprocessed to correct for head motion, eddy current, and B₀-field
468 inhomogeneity-induced geometric distortion using the Oxford FMRI Software Library (FSL)
469 DTI toolbox. Image slices with large within-slice intensity differences, wrapping abnormalities,
470 or other artifacts were identified by analysis with DTIPrep and subsequently removed. DTI
471 tractography was used to test for correlations between DTI parameters, the number of reported
472 TBIs, and symptom areas related to known brainstem functions. To conduct tractography,
473 DICOM-formatted diffusion images were converted to nrrd data file/header (nhdr) format
474 (<http://teem.sourceforge.net/nrrd/format.html>) in g-Fortran. Fiber tracts were created in SLICER
475 4.3.1 (<http://www.slicer.org/>). After the diffusion data were loaded into Slicer in nhdr format,
476 tensor estimates were created by converting the diffusion weights.

477 The resulting process created scalar measurements that were used to create corresponding
478 images of FA. The Editor module in Slicer was used to create a label map and a region of interest

479 (ROI) located in the four ROIs in the pons (**Fig. 4d**). Fiber tracts for each individual participant
480 were reconstructed from these seed regions using 1mm spacing thresholds, and the resulting fiber
481 tract vtk file was read into g-Fortran for quantitation of FA, mean diffusivity, radial diffusivity,
482 and axial diffusivity. These values were analyzed using nonparametric Spearman correlation
483 statistical analysis with respect to the $\log_{10}(\text{number of reported TBIs} + 1)$, hours of self-reported
484 nightly sleep, and other symptoms (**Fig. 4**), with final reported p-values controlled for multiple
485 comparisons using a rigorous 1% false discovery rate (FDR) adjustment. Each volume of interest
486 (VOI) had a volume of approximately 20mm^3 and was manually positioned. Evaluation of
487 pontine DTI averaged bilateral VOIs for rostral pontine (RP) and pontocerebellar (PC) tracts
488 with Montreal Neurologic Institute atlas x, y, z coordinates of (Left RP [-27.1, -20.0, -6.0]),
489 (Right RP [5.0, -20.0, -6.0]), (Left PC [-30.0, -38.0, -33.0]), and (Right PC [5.0, -38.0, -33.0]);
490 exemplars are found as white boxes in **Fig. 4d**.

491

492 **Animals**

493 Mice used in this study comprised group-housed, 3-to-6-month-old male C57Bl/6J wildtype,
494 $\text{Cx3cr1}^{\text{EGFP}}/\text{CCR2}^{\text{RFP}}$ [B6.129(Cg)-Cx3cr1tm1Litt-Ccr2tm2.1Ifc/JernJ (JAX stock # 032127)],
495 and microglial RiboTag mice [heterozygous offspring of B6.129P2(C)-Cx3cr1tm2.1(cre/ERT2)
496 mice (JAX stock # 020940)] crossed with RiboTag flox mice (JAX stock # 011029 B6N.129-
497 Rpl22tm1.1Psam/J). Animals were maintained on a 12-hour light/dark cycle with *ad libitum*
498 food and water access. All study procedures were in accordance with Association for Assessment
499 and Accreditation of Laboratory Animal Care guidelines and approved by the VA Puget Sound
500 Health Care System Institutional Animal Care and Use Committee.

501

502 **Modeling blast overpressure**

503 TBI was modeled with a shock tube designed to simulate open-field blast explosions (Baker
504 Engineering and Risk Consultants, San Antonio, TX) as described elsewhere.^{12,17} Briefly,
505 anesthetized mice were maintained on a non-rebreathing anesthesia apparatus (2% isoflurane in 1
506 Lpm oxygen) while secured on a gurney with their ventral side oriented toward the oncoming
507 blast overpressure wave and then placed into the shock tube. TBI mice were paired with sham
508 control mice and both were similarly secured in the shock tube while under anesthesia for an
509 identical amount of time. Mice received blast or sham procedures once per day, with 3x
510 treatment mice receiving one treatment per day for three days. The mean overpressure wave
511 characteristics for 102 blast overpressure waveforms generated in this experiment are 20.62+/-
512 0.15psi; 5.65+/-0.036ms; 0.038+/-0.00019psi·ms, including peak intensity (psi), initial pulse
513 duration (ms), and impulse (psi·ms), respectively. **Figure S2** displays an average of waveforms
514 from the study; this image, taken at random, consists of 102 overpressures and is consistent with
515 the accepted properties of mild to moderate blast exposure,^{17,62,63} resulting in a >95% survival
516 rate. After TBI and sham exposures, mice were monitored and generally regained normal
517 appearance within 4 hours of exposure.

518

519 **Tamoxifen treatments**

520 Three weeks after TBI or sham treatments, gene recombination was induced in microglial
521 RiboTag mice by two i.p. injections of tamoxifen (4mg in 200µl corn oil [Sigma, St. Louis, MO;
522 C8267]) that were administered two days apart.

523

524 **RiboTag immunoprecipitation**

525 Tamoxifen-treated Cx3cr1creER-Rpl22 RiboTag mice were deeply anesthetized with a lethal
526 injection of sodium pentobarbital (210 mg/kg, i.p.) followed by transcardial perfusion with PBS-
527 containing cycloheximide (100 μ g/ml). Brains were removed; subdissected on ice into brainstem,
528 cerebellum, and cortical hemisections; weighed; flash frozen; and stored at -80°C until used.
529 Upon use, approximately 20 to 30mg of each frozen tissue was cut and collected into RNase-free
530 tubes followed by homogenization by hand with a tube-fitting disposable pestle using 2-3%
531 weight per volume of the following buffer (HB-S): DTT (Sigma, St. Louis, MO; 646563, 1mM),
532 Protease Inhibitor Cocktail (Sigma, St. Louis, MO; P8340, 1x), RNAsin (Promega, Madison,
533 WI; N261B, 200 units/ml), cyclohexamide (Sigma, St. Louis, MO; C7698, 100 μ g/ml), heparin
534 (Sigma, St. Louis, MO; H3393, 100 mg/ml) in RNase-free deionized water. Homogenized
535 samples were centrifuge-clarified (12,000 x g, 10min, 4°C), and supernatants were transferred
536 into fresh RNase-free tubes followed by incubation (4°C for 4 hours with tube rotation) with
537 mouse monoclonal anti-HA.11 (Covance, MMS-101R, 3 uL/sample). After 4 hours, 200uL of
538 Protein A/G Magnetic Beads (Promega, Madison, WI; 88803) were added to each sample and
539 rotated at 4°C overnight. Beads were washed and pre-equilibrated in homogenization buffer and
540 blocked with 4% bovine serum albumin (Sigma, St. Louis, MO; 3117332001) for 1 hour prior to
541 use. The next day, mRNA transcripts and their associated antibody-bound ribosomes were
542 precipitated by magnet and washed (3 x 15 minutes each, 4°C with rotation) in 1 ml high salt
543 buffer (500 mM Tris pH 7.4, 300 mM KCl, 12 mM MgCl₂ 1% NP-40, 1 mM DTT, 100 μ g/ml
544 cyclohexamide in RNase-free water). Immediately after the final wash, transcripts were
545 dissociated from their precipitating complexes by addition of RLT Buffer (Qiagen, Germantown,
546 MD; 79216) supplemented with 10 μ l/ml RNase-free β -mercaptoethanol (Sigma, St. Louis, MO;
547 63689). RNA was purified by RNeasy Plus Micro kit (Qiagen, Germantown, MD; 74034)

548 according to manufacturer's protocol, followed by RNA quantification using a Nanodrop
549 spectrophotometer (ThermoFisher Sci, Waltham, MA). cDNA of precipitated transcripts was
550 made using the SuperScript VILO cDNA synthesis kit (ThermoFisher, Waltham, MA; 11754050)
551 according to the manufacturer's protocol. Yield of cDNA preparations was determined by
552 nanodrop (input: ~5ng/ μ l; immunoprecipitant: ~1.5-2.5 ng/ μ l). To verify enrichment of mouse
553 microglial genes, immunoprecipitants were analyzed in triplicate by real-time PCR on a
554 StepOnePlus Real-Time PCR System (ThermoFisher, Waltham, MA), using KAPA Universal
555 SYBR Green master mix and the following primers: Aif1(NM019467.3) forward 5'-
556 GGATTTGCAGGGAGGAAAAG, reverse 5'-TGGGATCATCGAGGAATTG; NTRK2
557 (NM008745.3) forward 5'-TGTTGCCTATCCCAGGAAGTG, reverse 5'-
558 CTGCAGACATCCTCGGAGATTA; GFAP (NM010277) forward 5'-
559 ACCATTCCTGTACAGACTTTCTCC, reverse 5'-AGTCTTTACCACGATGTTCTCTT;
560 GAPDH (NM008084) forward 5'-CTGCACCACCAACTGCTTAG, reverse 5'-
561 ACAGTCTTCTGGGTGGCA GT. Representative results are shown in **Figure S3**.
562 The following thermocycler settings were used: 95°C for 20 seconds followed by 40 cycles of
563 denaturation (95°C for 3 seconds), primer annealing and extension (60°C, 30 seconds) followed
564 by a melting curve. Gene expression was normalized within subjects to GAPDH levels and
565 quantified using the $2^{-\Delta\Delta CT}$ method. ROX was used as a reference dye.

566

567 **mRNA preparation and analysis**

568 RiboTag-immunoprecipitated mRNA was ribosomal RNA depleted using the Ribo Zero Gold
569 Magnetic system (Epicenter/Illumina, San Diego, CA). We prepared RNA-sequencing libraries
570 using ScriptSeq v2 kit (Epicenter) followed by single-end sequencing (1x50bp) on an Illumina

571 HiSeq 2500, generating 4×10^6 mean reads per sample. RNA-seq fastq files were aligned to the
572 mouse genome build *mm10* with *STAR* aligner and processed into transcript-level summaries
573 using the expectation maximization algorithm *RSEM*. Transcript-level summaries were
574 combined into gene-level summaries by adding all transcript counts from the same gene. Gene
575 counts were normalized across samples using *RLE* normalization, and the gene list was filtered
576 based on mean \log_2 (counts per million reads) > 4 in at least 3 samples in any group, which left
577 about 14,000 “detected” genes for further analysis. Consistency of replicates was inspected by
578 principal component analysis using *R*. Differential expression was assessed through sequential
579 analyses of both an initial discovery cohort to identify candidate genes ($\alpha=0.05$) and a secondary
580 validation cohort ($\alpha=0.05$). The candidate differential genes, defined as the shared set of
581 overlapping genes, was further evaluated. Forty-percent of the identified candidate differentially
582 expressed genes have been previously reported (**Table S1**).

583 Gene set enrichment analysis (GSEA) was conducted in DAVID
584 (<https://david.ncifcrf.gov/tools.jsp>) using the full list of candidate differentially expressed genes
585 for brainstem. Official gene symbols were queried against the *Mus musculus* species using the
586 default settings for analyses conducted by DAVID. Gene Ontology terms with Benjamini-
587 corrected $p < 0.05$ were reported.

588

589 **Data availability**

590 Data are available through reasonable requests addressed to the corresponding author.

591

592 **Neurovascular permeability studies**

593 Radiolabeled tracer preparation: Albumin (Sigma, St. Louis MO) was radiolabeled using
594 established protocols⁶⁴ with ^{99m}Tc (GE Healthcare, Piscataway, NJ). Hydrochloric acid was used
595 to pH-adjust a solution of aqueous stannous tartrate (240 mg/ml) and albumin (1 mg/ml) to a
596 final pH of 3.0 before the addition of one millicurie of ^{99m}Tc-NaOH₄ to the mixture, which was
597 then allowed to react for 20 min. The resulting radiolabeled ^{99m}Tc-albumin was column-purified
598 (G-10 Sephadex; GE Healthcare, Piscataway, NJ) in 0.1 ml fractions of phosphate buffer (250
599 mM). Purified ^{99m}Tc-albumin was > 90% acid precipitable in 1% bovine serum albumin and
600 trichloroacetic acid (30%) (1:1 mixture). Each mouse was administered 5×10^6 counts per
601 minute (cpm) of purified ^{99m}Tc-albumin fraction in 0.2 ml lactated Ringer's solution containing
602 1% BSA. ¹⁴C-sucrose was supplied as an ethanol-dissolved product (GE Healthcare, Piscataway,
603 NJ). Ethanol was evaporated before use and resuspended at 1×10^7 cpm in 1% BSA lactated
604 Ringer's solution. Radiolabeled tracer injections: At 15 minutes, 24 hours, or 72 hours after
605 mTBI or sham treatments, mice were anesthetized with urethane (4 g/kg; 0.2 ml; i.p.) followed
606 by exposure of the jugular vein and injection with ¹⁴C-sucrose or ^{99m}Tc-albumin in 0.2 ml of
607 lactated Ringer's solution with 1% BSA for 10 minutes. The descending abdominal aorta was cut
608 to collect blood. Vascular contents of the brain were cleared by left cardioventricular perfusion
609 (20 ml lactated Ringer's solution per minute) after clamping the descending thoracic aorta and
610 severing both jugular veins. Two brains with incomplete blood washout were excluded from
611 analysis. After perfusion, the brain was removed; subdivided into cortical hemispheres,
612 brainstem, and cerebellum; and individually weighed. The analytical results of these experiments
613 with respect to cerebellum were recently published by our group.⁶⁴ Radioactivity was calculated
614 as cpm/g tissue or cpm/ml serum, as appropriate. The brain tissue radioactivity was then divided
615 by the corresponding serum radioactivity to yield units of microliters/gram of brain tissue.

616

617 ***In vivo* dextran labeling of injured cells**

618 Extravasation of blood-borne dextran to label coincident vascular and neural injury was
619 accomplished as described elsewhere.¹⁷ Briefly, following induction of isoflurane anesthesia
620 prior to TBI or sham procedures, mice were injected with 100 µl of 400 mg/ml 10kDa dextran
621 labeled with tetramethylrhodamine (Life Technology, Grand Island, NY) into the retro-orbital
622 sinus. After TBI or sham treatments, mice then recovered for 1 or 4 hours before euthanasia and
623 transcardial perfusion with phosphate-buffered saline followed by 4% formalin.

624

625 **Animal MRI**

626 MR imaging was acquired on 12 mice (6 sham and 6 single mTBI) at 24 hours post-injury and
627 again at 30 days post-injury. Mice were anesthetized with isoflurane and scanned over the entire
628 brain using a high-resolution 14 T MRI (Avance III, vertical bore, Bruker BioSpin Corp,
629 Billerica, MA). T2 quantitative mapping (T2) was acquired with a voxel size of 0.12 x 0.12 x 1.0
630 mm³, 15 slices, TR 1/4 2000 ms, 16 echoes, spacing: 6.7 ms, TE Effective 1: 6.7 ms, TE Effective
631 2: 13.4 ms, and was used to measure ventricular volume and scan for evidence of parenchymal
632 bleeding within visible areas. All analyses were performed by a blinded investigator (DJC).
633 Analysis of T2 quantitative maps required threshold bounding set from 36 to 200, which
634 included ROIs but excluded normal cortex and white matter. Manually drawn ROI analysis was
635 performed using Image J software. ROIs included the volume of voxels within the threshold
636 boundary comprising the lateral, 3rd, and 4th ventricles, across a total of seven image slices, and
637 total volumes were calculated by multiplying with voxel size in mm³.

638 **Mouse sleep assessments**

639 Noninvasive measurements of sleep bout duration and the sleep:wake ratio were acquired using
640 an automated sleep/wake scoring system designed for rodents (PiezoSleep; Signal Solutions,
641 Lexington, KY). One week after the final TBI or sham procedure and again three months later,
642 mice were placed in open-floored chambers installed with piezoelectric sensors are designed to
643 detect and track the previously characterized sleep activity of mice.⁶⁵ Mice were allowed to
644 acclimate for 2 days before their undisturbed activity was recorded over the next 3 days
645 following previously established methods.^{37,66} Data were analyzed using the Sleep Statistics
646 Toolbox (Signal Solutions, Lexington, KY).

647

648 **Microscopy**

649 Microscopy was performed as described elsewhere.¹⁷ Briefly, brains were post-fixed in 10%
650 neutral buffered formalin at 4°C for 3 to 5 days followed by 24 hours of equilibration in 30%
651 sucrose/PBS prior to embedding in OCT (Tissue-Tek, Torrance, CA). Antigen retrieval was
652 performed using 50 mM of sodium citrate (pH 8.0) with heat (80°C, 30 min). Cryopreserved
653 floating tissue sections were permeabilized with 1% Tx-100 (Sigma, St. Louis, MO), blocked
654 with 10% bovine serum albumin (1 hour, room temperature), and immunostained and mounted
655 using Prolong Gold Antifade Reagent (ThermoFisher, Waltham, MA). The following antibodies
656 were used overnight at 4°C: mouse anti-CNPase clone SMI-91 (Biolegend, Dedham, MA;
657 1:1,000), astrocyte marker anti-GFAP (Millipore, Billerica, ME; 1:1000), neuronal marker anti-
658 neurofilament-heavy chain (Nf-HC) (Aves, Tigard, OR; 1:1000), mouse monoclonal TauC3
659 (ThermoFisher, Waltham, MA; 1:1000), rabbit anti-phospho Tau 396 (AnaSpec, Fremont, CA;
660 1:1000), and mouse monoclonal anti-Iba-1 (Wako Chemicals, Richmond, VA; 1:1,000).
661 Corresponding secondary antibodies were applied for 2 hours at room temperature (Jackson

662 Immunoresearch, West Grove, PA; 1:1,000). Confocal microscopy was performed with a Leica
663 TCS SP5 II with tunable emission gating. Representative brainstem regions imaged for analyses
664 are identified in **Supplemental Figure 5**. To quantify the degree of myelin internalization by
665 microglia, z-plane images of tissue areas (approximately 600 μm x 600 μm x 50 μm) were
666 acquired by performing sequential, between-stack, single-photon excitation at 488 nm and 543
667 nm using system optimized stepping (~ 2 μm). Images were acquired with the Leica Application
668 Suite and processed using linear contrast and brightness adjustments applied identically and
669 simultaneously to all data being directly compared within each experiment.

670

671 **Imaging mass cytometry**

672 Metal-conjugated antibodies were either purchased (Standard Biotech, San Francisco, CA) or
673 custom-made by conjugation using the MaxPar X8 labelling kit (Standard Biotech, San
674 Francisco, CA) and carrier and preservative-free antibody formulations following the
675 manufacturer protocol. Typical antibody recovery was $59 \pm 0.16\%$. Tissue staining with metal-
676 labeled antibodies was similarly accomplished using the manufacturer's protocol for formalin-
677 fixed paraffin-embedded slides with minor modifications. Briefly, tissue sections of either
678 formalin-fixed human paraffin embedded tissues or covalently bound, agarose-block embedded
679 mouse brain sections were used for imaging mass cytometry. Paraffin embedding and sectioning
680 followed standard histological procedures, whereas preparation of agarose-block embedded
681 brains followed procedures developed and published by the Allen Institute for Brain Science for
682 use in serial two-photon tissue tomography ([dx.doi.org/10.17504/protocols.io.bf65jrg6](https://doi.org/10.17504/protocols.io.bf65jrg6)). One
683 each TBI and sham mouse brain were randomly paired and embedded together into the agarose
684 block. The brains were oriented in parallel such that the sham brain cortex was always oriented

685 facing outward. Agarose block–embedded sections were cut at 50 μm thickness (immediately
686 after aqueous two-photon imaging). Slices cut from agarose block–embedded brains were
687 robotically mounted with a TissueVision 1600FC SlicerPlacer module (Tissuecyte, Newton,
688 MA) onto superfrost plus slides (Thermo Fisher Scientific Bothell, WA) and subsequently air-
689 dried for up to one year before use. DNA intercalator (Iridium 191/193, 201192B; Standard
690 Biotools, San Francisco, CA) was diluted 1:4000 in Dulbecco’s phosphate buffered saline
691 (21600-051, in 18.2 M Ω water; Thermo Fisher Scientific; Bothell, WA) for 30 minutes at room
692 temperature before slides were washed in 18.2 M Ω water, air-dried overnight, and stored at room
693 temperature until used.

694 Coronal brainstem hemisections were routinely ablated using the Hyperion UV laser
695 system with 1 μm^2 diameter (Standard Biotools, San Francisco, CA). The ablated materials are
696 carried by helium into the Helios mass cytometer, which uses a time-of-flight mass detector to
697 detect and timestamp the abundance of a user-defined mass range for each rasterized 2-
698 dimensional location.⁶⁷ The Hyperion instrument was tuned daily according to the
699 manufacturer’s protocol.

700

701 **Single cell gating, analysis, and image visualization**

702 Imaging mass cytometry datasets were collected in MCD file format and exported as single
703 channel TIFs for bulk import into CellProfiler. There, segmentation of single cells based on the
704 watershed gradient algorithm using DNA intercalator channels (191Ir, 193Ir) and a proprietary
705 mix of plasma membrane markers (channels 195Pt, 196Pt, 198Pt; IMC Cell Segmentation Kit,
706 TIS-00001; Standard Biotools, San Francisco, CA) was performed to define cell nuclei and
707 single cell boundaries, respectively. Microglia were gated by selecting cells with marker

708 intensities for CCR2⁻(<2.5) and Iba1⁺ (> 6) to delineate them from peripheral immune cells
709 expressing higher levels of CCR2. DAMs were gated by selecting the following parameters:
710 Iba1 > 6, CD68 > 10, CCR2 < 2.5, ApoE > 8, and CD63 >2. The thresholds for CCR2, ApoE,
711 and CD63 positive signals was determined by comparison of the CD63⁺ microglial cells that
712 were identified by manual observation, relative to other cell types. The threshold for CD68 high
713 or low signal was determined by the comparison to manually identified microglia in sham
714 control animals establishing the lower limit. All major cell types, including astrocytes, neurons,
715 oligodendrocytes, peripheral immune cells, and vascular endothelium, were validated by manual
716 annotation.

717 Brainstem images were aligned to the Allen mouse brain reference map⁶⁸ and segmented
718 by anatomical region in HistoCAT.⁶⁹ Using HistoCAT, Barnes-Hut t-SNE, and phenograph,
719 neighborhood analyses (using a proximity of 6) were conducted using default settings. Images
720 representing single and merged channels, such as **Fig. 2f**, were saved as TIF files via MCD
721 viewer software (Fluidigm), imported into Adobe Photoshop 2021 (Adobe Systems, San Jose,
722 CA), and processed with a Gaussian blur filter to de-speckle images. Afterward, all images being
723 directly compared within a figure panel were uniformly and simultaneously adjusted to optimal
724 brightness and contrast levels using a single adjustment mask.

725

726 **Western blot analyses**

727 Brains were dissected in PBS on ice. Protein lysates were prepared as described elsewhere.¹⁷
728 Briefly, phosphatase inhibitor cocktail sets 2 and 3 (Sigma, St. Louis, MO) were added (10
729 µl/ml) to lysis buffer, and tissues were homogenized twice by hand using an Eppendorf tube-
730 fitting pestle (Eppendorf, Hauppauge, NY) before centrifuge clarification at 12,000xg for 10

731 minutes. TGX Criterion 4-20% SDS-polyacrylamide gels (Bio-Rad, Hercules, CA) were loaded
732 with 20 µg protein per lane using supernatants of the clarified lysates from individual animals.
733 Membranes were then blocked with 10% nonfat milk (1 hour at room temperature) and probed
734 with antibodies recognizing the following targets: anti-pathological tau clones AT8 and AT270
735 (Thermo Fisher Scientific, Rockford, IL); anti-mouse tau (total) clone Tau5 and anti-phospho
736 Tau S396 (Life Technologies, Grand Island, NY); MOBP (Genetex, Irvine, CA); CNPase
737 (Biolegend, San Diego, CA); mouse anti-MBP and rabbit antibodies anti-LINGO1, anti-GFAP,
738 and anti-MnSOD (EMD-Millipore, Billerica, MA); and Pyruvate kinase (Rockland, Gilbertsville,
739 PA). Probes for the load control protein, pyruvate kinase, were conducted after stripping.

740

741 **Causal mediation analysis**

742 Mediation analysis evaluates the statistical probability of a known third (declared) variable to
743 mediate the primary relationship between independent and dependent variables. The effect of
744 changes in pontine FA (adjusted for age and PCL-M total scores for PTSD symptom severity) to
745 mediate behavioral and physiological symptoms (dependent variables) following self-reported
746 TBI (independent variable) was first evaluated with multivariable linear regression in R (**Fig. 4j**).
747 A subsequent validation analysis was conducted with the R statistical package Mediate using
748 nonparametric bootstrapping procedures and also used age- and PTSD symptom severity-
749 adjusted pontine FA (**Fig. 4k**). This indirect effect is measured as the portion of the relationship
750 between two variables mediated by the third variable.^{70,71} In validation analyses, unstandardized
751 indirect effects were computed thrice for each of 10,000 bootstrapped samples, and the 95%
752 confidence interval was computed by determining the indirect effects at the 2.5th and 97.5th
753 percentiles. Sensitivity analyses were conducted in R and are illustrated in **Figure S5**.

754

755 **Statistical analyses**

756 Data are presented as distributions (violin plots) or mean \pm standard error of the mean (bar
757 graphs). Multivariable linear regression: Standard analysis of variance (ANOVA) was used for
758 planned statistical tests involving multiple measures or groups. False discovery rate-adjusted
759 post-hoc analyses with $\alpha = 0.05$ were conducted as indicated. T-tests were used for planned
760 comparisons involving two normally distributed groups, with nonparametric Mann-Whitney tests
761 used for unpaired comparison of non-normal distributed groups. Bivariate linear or simple linear
762 regression was used to predict DAM frequency based on IL-33 expression. Multivariate linear
763 regression analysis reported correlations adjusted for age, depression, PTSD symptom severity,
764 sleep apnea, and alcohol use. Statistical significance was defined as $p \leq 0.05$. Sample sizes were
765 based on previous reports.^{17,60,72} All analyses were determined using Prism 8.4 (GraphPad, San
766 Diego, CA), SPSS software (IBM, Armonk, NY), or R version 3.6.1 (R Core Team, Vienna,
767 Austria).

768

769 **Acknowledgments**

770 Author contributions

771 JSM: Conceptualization, formal analysis, supervision, funding acquisition, investigation,
772 visualization, writing—all drafts, writing—review and editing; AGS, MMC, AFL, CM, AC,
773 JRP, AS-D, and RGT, KFP, DAM, CDK: Formal analysis, investigation; MY: Validation; TLR
774 and KDM: Formal analysis, performed the DTI analyses; DJC and DGC, DRM, JWR, MO:
775 Investigation; DPP, WAB, JPM, MAR, EAC, CLS, CDK, DAM and ERP: Conceptualization,
776 resources.

777 We'd like to thank Dr. Erica Melief and Aimee Schantz for outstanding administrative
778 support, and Lisa Keene, Amanda Keen, and Katelyn Kern for expert technical assistance, and
779 the incredible generosity of the military Veteran and civilian participants, and their families,
780 without whom this work would be impossible.

781

782 Funding

783 This study was supported by the Veterans Affairs Office of Biomedical Laboratory Research &
784 Development (JSM, I01BX004896; DGC, I01BX002311; AGS, 1IK2BX003258), VA
785 Rehabilitation Research & Development (ERP, I01RX000521, I01RX001612, I01RX003087),
786 VA Puget Sound R&D Seed grant (JSM), University of Washington Friends of Alzheimer's
787 Research (DGC, ERP), UW Royalty Research Fund (DGC), and the Northwest Network Mental
788 Illness Research, Education, and Clinical Center (JSM, MAR, ERP). Human brain tissue
789 specimens were derived from the Uniformed Services University neuropathology repository
790 (D.P.), University of Washington BioRepository and Integrated Neuropathology (BRaIN)
791 Laboratory with support from the Nancy and Buster Alvord Endowment (to C.D.K.), the Henry
792 Jackson Foundation, and the Neuropathology Core of the UW Alzheimer's Disease Research
793 Center (P30 AG066509).





Figure 1. Pontine nuclei are vulnerable to a single blast mTBI.


a, Time course and quantitation of blood-borne small (^{14}C -sucrose) and large ($^{99\text{m}}\text{Tc}$ -albumin) molecule extravasation into brainstem, cortex, and whole brain. **b**, Time course and distribution of injured neurons labeled with a blood-borne fluorescent dye as observed using confocal microscopy. **c**, Injured cell distributions viewed across white vs. gray matter. **(b)** and **(c)** show the average number of animals per experiment with labeled cells (mice, 1 hr: N=35,35; 4 hr: N=40,40; average ~5 mice per group per cohort; 7 cohorts). **d**, Representative micrographs of injured, dye-labeled neurons and accompanying microglial response 1 hr following TBI. Staining of injured pontine cells is subtle compared to cerebellar Purkinje cells. PRNR, rostral pontine reticular nucleus. **e**, Example micrographs of injured locations often observed. RF, reticular formation. **f**, Western blots document increasing tauopathy (Tau396, AT8, AT270; axon injury markers) and gliovascular injury (aqp4) during the 1-4 hr acute inflammatory phase after a single diffuse mTBI (5 mice/group). Tau5, total tau; PK, pyruvate kinase (load control). **g** and **h**, Confocal micrographs of **(g)** caspase-cleaved Tau (Tau C3) and **(h)** pathologically associated tau hyperphosphorylation (pS396) in the pons 1 day after TBI. **i**, Representative T2 MRI of mice 24 hrs after a single TBI or sham procedure. Red color indicates pixels that exceed the threshold value (representative of CSF) and green is the region-of-interest (ROI) bounding box. **j**, Quantification of ventricle volumes (6 mice/group). One-way ANOVA (**a**), two-way ANOVA (**c**, **j**), and mixed effects model (**b**). Scale bars are 100 μm .

000



839
840


841 **Figure 2. mTBI induces persistent pontine microgliopathy.** **a**, Discovery and validation
842 strategy using 3-month-old male Cx3cr1^{CreER}:Rpl22^{HA} RiboTag mice to identify genes actively
843 transcribed and differentially expressed in myeloid cells one month after repeated (3x) mTBI as
844 compared to sham control mice. **b**, Heatmaps of candidate differentially expressed genes (DEGs)
845 identified by RNA sequencing across brain regions. **c**, False discovery rate-adjusted p-values for
846 candidate DEGs. **d**, Gene Ontology terms significantly associated with brainstem DEGs.
847 Benjamini adjusted p-values. **e**, Imaging mass cytometry (IMC) workflow for detecting and
848 phenotyping changes in brain tissue microenvironments after injury. **f**, T-SNE-based global
849 phenotyping of single-cell image data. **g**, Phenograph analysis with unbiased identification of
850 disease associated microglia (DAMs) (cluster 26, red box; CCR2⁻, Iba-1⁺, CD68^{hi}, ApoE^{hi}). **h**,
851 Neighborhood analysis identifying changes in the frequency of associations between DAMs
852 (Phenograph cluster 26) and phenograph-defined tissue microenvironments.



853
854
855
856
857
858
859
860
861
862

Figure 3. mTBI-induced IL33 release by oligodendrocytes is associated with microglial-mediated myelin remodeling. **a**, Representative IMC images of pontine hemisections from repeated TBI and sham mice. **b**, Average frequency of DAM per subject detected in IMC across pontine regions. **c**, Average expression of oligodendrocyte IL33 per mouse measured across pontine regions. **d**, Redistribution of nuclear oligodendroglial IL33 into the surrounding parenchymal microenvironment measured as a frequency histogram of IL33 signal intensity across pixels from insets in **(a)**. **e**, Quantitation of microglial-specific IL33R transcript determined from microglial RiboTag mice (N=7 sham, 8 TBI (3x)). **f**, Release of

863 oligodendroglial IL33 predicts the accumulation of DAMs. DAM frequency significantly
864 increased with loss of oligodendroglial IL33 among all pontine regions. Linear regression model.
865 **g**, Volcano plot of q values (FDR-adjusted p-values) identifying robust myelin injury in the
866 pontine RF, as measured by IL33 depletion from oligodendrocytes. **h**, Example of maximum
867 intensity projection images from 3D confocal micrographs of microglia (red, Iba1) and myelin
868 CNPase (green). Arrowheads denote microglial nodules consuming myelin. **i**, Violin plots show
869 the total amount of CNPase internalized by microglial cells in each $50\mu\text{m} \times 632\mu\text{m}^2$ 3D confocal
870 image. **j**, Length of average sleep bouts and (**k**) sleep-to-wake ratios at 1 week and 3 months
871 after repeated TBI. Red represents TBI data; blue represents sham control data. Data are a
872 distribution of measured means from individual mice. Regions in (**b,c,g**) correspond to map in
873 **Fig. 2e**. dm, dorsal medulla; rf, pontine reticular formation; scp, superior cerebellar peduncle;
874 spn, spinal trigeminal nerve tract; vco, ventral cochlear nucleus; vm, ventral medulla.



875
876 **Figure 4. Pontine myelin injury mediates chronic blast-mTBI symptoms.** **a**, Representative
877 examples of brainstem glia in blast-mTBI and control subjects observed in three separate clinical
878 neuropathology labs. **b**, Example confocal micrograph of clinical microglial nodule (red) with
879 apparent internalization of myelin CNPase (green). **c**, ICM of pontine DAM (arrowheads)
880 phagocytosing a neuron as seen in a clinical TBI subject. Purple, NeuN; cyan, CNPase; green,
881 Iba-1; red, CD68; white, GFAP; blue, H3K27Me3. **d**, DTI tractography generated from pontine
882 seed points. Boxes indicate the approximate locations of volumes of interest (VOIs) used for
883 clinical DTI measures of major pontine projection tracts. Seed points were selected based on the
884 acute pontine injury pattern observed in our animal study. CR, corona radiata; SCP, superior
885 cerebellar peduncle. **e-h**, Quantification of chronic myelin injury is averaged across VOIs in
886 living subjects. **e**, DTI fractional anisotropy (FA) is reduced in TBI subjects compared to control
887 subjects; with groupwise changes in **(f)** axial and **(g)** radial anisotropy. **h**, Cumulative TBI-dose
888 dependent decreases in pontine FA values adjusted for age and PTSD severity using linear
889 regression modeling. **i**, Path diagram for causal mediation modelled with multivariable linear
890 regression. ACME: adjusted causal mediation effect estimate, DE: direct effect estimate, ADE:
891 adjusted direct effect estimate, TE total effect estimate. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. **j**,
892 ACMEs for NSI+ total score related to blast-mTBI as mediated by reductions in mean pontine
893 fiber FA (adjusted for age and PTSD). **k**, Results of bootstrap validation of mediation path
894 illustrated in **(j)**. **l**, Boot-strap validated mediation analysis of blast-induced pontine fiber injury

895 to cause sleep injury using PTSD and age-adjusted PSQI total scores. Two-tailed t-tests in **(e-g)**.
896 Scale bars are **(e)** 100 μ m and **(b, i)** 10 μ m.

897 Supplemental Table 1.
898 **Table S1. Table of candidate DEGs previously reported**

	Ensembl gene number	Official Gene Symbol	Mouse Genome Informatics ID	UniProtKB	Previous Reports by PubMed ID
Candidates in Frontal Cortex	ENSMUSG00000027122.15	<i>Arl14ep</i>	MGI:1926020	Q8BIX3	
	ENSMUSG00000073102.7	<i>Drc1</i>	MGI:2685906	Q3JUS3	
	ENSMUSG00000056116.18	<i>H2-T22</i>	MGI:95956	Q31615	
	ENSMUSG00000072294.5	<i>Klf12</i>	MGI:1333796	Q35738	
	ENSMUSG00000090553.8	<i>Snrpe</i>	MGI:98346	P62305	
	ENSMUSG00000046985.11	<i>Tapt1</i>	MGI:2683537	Q4VBD2	
	ENSMUSG00000041353.12	<i>Tmem29</i>	MGI:1923420	A2ANF5	
	ENSMUSG00000041747.3	<i>Utp15</i>	MGI:2145443	Q8C7V3	
ENSMUSG00000103567.1	<i>Pcdhga5</i>	MGI:1935217	Q91XY3		
Candidates in Cerebellum	ENSMUSG00000024998.17	<i>Plice1</i>	MGI:1921305	Q8K4S1	
	ENSMUSG00000064043.13	<i>Trerf1</i>	MGI:2442086	Q8BXJ2	
	ENSMUSG00000022382.15	<i>Wnt7b</i>	MGI:98962	P28047	
	ENSMUSG00000030697.7	<i>Ppp4c</i>	MGI:1891763	P97470	
	ENSMUSG00000056306.5	<i>Sertm1</i>	MGI:3607715	Q8CD78	
	ENSMUSG00000037761.16	<i>Actr5</i>	MGI:1924748	Q80U54	
	ENSMUSG00000033021.16	<i>Gmppa</i>	MGI:1916330	Q922H4	
	ENSMUSG00000021884.18	<i>Hac11</i>	MGI:1929657	Q9QXE0	
	ENSMUSG00000032360.16	<i>Hcrr2</i>	MGI:2680765	P58308	
	ENSMUSG00000046523.5	<i>Kctd4</i>	MGI:1914766	Q9D7X1	
	ENSMUSG00000030226.12	<i>Lmo3</i>	MGI:102810	Q8BZL8	
	ENSMUSG00000024146.9	<i>Cript</i>	MGI:1929655	O70333	
	ENSMUSG00000052928.8	<i>Ctif</i>	MGI:2685518	Q6PEE2	
ENSMUSG00000048644.8	<i>Ctxn1</i>	MGI:88566	Q8K129		
Candidates in Brainstem	ENSMUSG00000011148.14	<i>Adss1</i>	MGI:87947	P28650	
	ENSMUSG00000021557.15	<i>Atgabp1</i>	MGI:2159437	Q641K1	
	ENSMUSG00000025135.12	<i>Anapc11</i>	MGI:1913406	Q9CFX9	
	ENSMUSG0000002985.16	<i>Apoe</i>	MGI:88057	P08226	30082275, 33333014, 30471926, 30185219, 31998844, scrnaseq: 33257666, 28602351, 30206190, 32371549, 31768052, 31061494, mass cytometry: 31740814, 32811567, 11406294, 17900569, 11556547
	ENSMUSG00000076441.9	<i>Ass1</i>	MGI:88090	P16460	
	ENSMUSG00000038539.15	<i>Atf5</i>	MGI:2141857	O70191	
	ENSMUSG00000019943.10	<i>Atp2b1</i>	MGI:104653	G5E829	
	ENSMUSG00000022956.11	<i>Atp5o</i>	MGI:106341	Q9DB20	
	ENSMUSG00000006273.14	<i>Atp6v1b2</i>	MGI:109618	P62814	
	ENSMUSG00000002602.16	<i>Axl</i>	MGI:1347244	Q00993	30471926, 30185219, scrnaseq: 33257666, 28602351, 30206190, 31061494, 33029008
	ENSMUSG00000043300.2	<i>B3galnt1</i>	MGI:1349405	Q920V1	
	ENSMUSG00000051223.14	<i>Bzw1</i>	MGI:1914132	Q9CQC6	
	ENSMUSG00000056737.14	<i>Capg</i>	MGI:1098259	P24452	30082275
	ENSMUSG00000019122.8	<i>Ccl9</i>	MGI:104533	P51670	32059938
	ENSMUSG00000034652.12	<i>Cd300a</i>	MGI:2443411	Q65IQ0	
	ENSMUSG00000000682.7	<i>Cd52</i>	MGI:1346088	Q64389	ribotag: 30082275, scrnaseq 30471926, 30185219, 31998844, 30206190
	ENSMUSG00000018774.13	<i>Cd68</i>	MGI:88342	P31996	26764157, ribotag: 33333014, nanostring: 31440141, 33452227, scrnaseq: 33257666, 30206190, 31061494, 33029008, mass cytometry: 31740814, 32470397, 32917850, 32917850, 31440141, scrnaseq: 33257666
	ENSMUSG00000015396.4	<i>Cd83</i>	MGI:1328316	Q88324	
	ENSMUSG00000046722.14	<i>Cdc42se1</i>	MGI:1889510	Q8BHL7	
	ENSMUSG00000050370.4	<i>Ch25h</i>	MGI:1333869	Q920F5	ribotag: 29777220, scrnaseq: 31998844, 32371549
	ENSMUSG00000068129.5	<i>Cst7</i>	MGI:1298217	O89098	30082275, 30471926, 31998844, scrnaseq: 33257666, 28602351, 30206190, 31061494
	ENSMUSG00000021939.8	<i>Ctsb</i>	MGI:88561	P10605	30185219, 31998844, scrnaseq: 33257666, 28602351, 30206190, 32371549, 31061494, 33029008
	ENSMUSG00000037149.10	<i>Ddx1</i>	MGI:2144727	Q91VR5	
	ENSMUSG00000063904.3	<i>Dpp3</i>	MGI:1922471	Q99KK7	
	ENSMUSG00000022842.18	<i>Ece2</i>	MGI:1101356	B2RQR8	19541930
	ENSMUSG00000038418.7	<i>Egr1</i>	MGI:95295	P08046	31998844, scrnaseq: 32371549, 31061494
	ENSMUSG00000058655.9	<i>Eif4b</i>	MGI:95304	Q8BGD9	
	ENSMUSG00000074802.11	<i>Gas2l3</i>	MGI:1918780	Q3UWV6	
	ENSMUSG00000072772.3	<i>Grccl0</i>	MGI:1315201	Q35127	
	ENSMUSG00000020330.16	<i>Hmnr</i>	MGI:104667	Q00547	
	ENSMUSG00000050335.17	<i>Hgals3</i>	MGI:96778	P16110	30082275, 30471926, 31998844, scrnaseq: 33257666, 29020624, 31061494
	ENSMUSG00000015568.16	<i>Lpl</i>	MGI:96820	P11152	30082275, 30471926, 31998844, scrnaseq: 33257666, 28602351, 30206190
	ENSMUSG00000034854.8	<i>Mfsd12</i>	MGI:3604804	Q3U481	
	ENSMUSG00000033307.7	<i>Mif</i>	MGI:96982	P34884	scrnaseq 30471926 (development), 31998844, 33029008
	ENSMUSG00000022453.8	<i>Naga</i>	MGI:1261422	Q9QWR8	
	ENSMUSG00000027698.14	<i>Nceh1</i>	MGI:2443191	Q8BFL1	
	ENSMUSG00000041560.12	<i>Nop53</i>	MGI:2154441	Q8BK35	
	ENSMUSG00000040771.14	<i>Oard1</i>	MGI:2146818	Q8R5F3	
	ENSMUSG00000023191.9	<i>P3h3</i>	MGI:1315208	Q8CG70	
	ENSMUSG00000046139.7	<i>Pat11</i>	MGI:2147679	Q3TC46	
	ENSMUSG00000031921.17	<i>Terf2</i>	MGI:1195972	Q35144	
	ENSMUSG00000027750.16	<i>Postn</i>	MGI:1926321	Q62009	25580734 (in glioma, recruits macs)
	ENSMUSG00000022951.16	<i>Rcan1</i>	MGI:1890564	Q9JHG6	20967884, 23144708, 18485347,
	ENSMUSG00000032518.6	<i>Rpsa</i>	MGI:105381	P14206	19196078
	ENSMUSG00000039153.16	<i>Runx2</i>	MGI:99829	Q08775	24768841 runx2 driven by P2X7 activity
	ENSMUSG00000024737.2	<i>Slc15a3</i>	MGI:1929691	Q8BFX9	
	ENSMUSG00000069793.12	<i>Sifn9</i>	MGI:2445121	B1ARD6	
ENSMUSG00000029304.14	<i>Spp1</i>	MGI:98389	P10923		
ENSMUSG00000029538.14	<i>Srsf9</i>	MGI:104896	Q9D0B0	30082275, 31998844, 28101531, 31088570, 15804504, 12132583, scrnaseq: 28602351, 33029008	
ENSMUSG00000031995.9	<i>Stt14</i>	MGI:1338881	P56677	30082275	
ENSMUSG00000022415.12	<i>Syngr1</i>	MGI:1328323	O55100	scrnaseq of ALS mouse brainstem: 32360664	
ENSMUSG00000037108.13	<i>Zcwpw1</i>	MGI:2685899	Q6IR42	26919393 (AD risk polymorphism associated with microglial expression)	
ENSMUSG00000027506.15	<i>Tpd52</i>	MGI:107749	Q62393		
ENSMUSG00000056019.12	<i>Zfp709</i>	MGI:2384299	Q99P16		

901 Supplemental Table 2.

902

903 **Table S2. Table of imaging mass cytometry antibodies**

Mass Channel	Antibody	Supplier	Supplier Cat #	LOT #	[ug/ml] (final)	Validation
141	mouse monoclonal anti- human Smooth muscle Actin (Clone 1A4)	FLUIDIGM	3141017D	1261907	2	endogenous expression in Human, rat, mouse; KO validated for IHC / IF / WB
142	rabbit monoclonal anti- human APP y188	Abcam	ab256586	GR3337706-2	6.5	endogenous expression in Human, rat, mouse; KO validated for IHC / IF / WB
143	rabbit monoclonal anti- human AQP4 (Clone D1F8E)	Cell Signaling Technologies	59678BF	2	8	endogenous expression in Human, rat, mouse; validated by IHC / IF / WB / IP
144	rabbit monoclonal anti- mouse calbindin (Clone EPR22698-236)	Abcam	ab255691	GR3279332-2	3	endogenous expression in rat, mouse; validated by IHC / IF / WB / IP
145	rabbit monoclonal anti- mouse CD63 (Clone EPR21151)	Abcam	ab227892	GR3274484-1	8	endogenous expression in mouse; validated by IF / WB
147	rabbit monoclonal anti-CD31 (Clone D8V9E)	Cell Signaling Technologies	92841BF	3	1.6	endogenous expression, with positive and negative controls
148	mouse monoclonal anti- human pan cytokeratin (C11)	FLUIDIGM	3148020D	1681901	2.5	endogenous expression in rat, mouse; validated by IHC / IF
149	rabbit monoclonal anti- h3k27me3 (Clone C36811)	Cell Signaling Technologies	97338BF	20	5	endogenous expression in rat, mouse, human; validated by IHC / IF / WB / IP
150	rat monoclonal anti- mouse CD3 (Clone 17A2)	Biolegend	100238	B305614	10	endogenous expression for mouse, reported applications FC, ICFC, ICC, IHC, IP, WB, FA
151	rabbit monoclonal anti- thrombospondin (Clone EPR22928-10)	Abcam	ab263952	GR3297011-2	6.5	endogenous expression in rat, mouse, human; validated by IHC / IF / WB / IP
152	rabbit monoclonal anti- htt (Clone EPR5526)	Abcam	ab209668	GR3271602-1	3.3	endogenous expression in human, rat, mouse; KO validated, for IHC / IF / WB / Flow Cyt
153	rat monoclonal anti- mouse CD8a (Clone 53-6.7)	FLUIDIGM	clone 53-6.7	101806	6.5	endogenous expression in mouse; validated, for IF / Flow Cyt
154	rabbit monoclonal anti- mouse CCR2 (Clone EPR20844-15)	Abcam	ab273061	GR3341831-1	12.5	endogenous expression in mouse, rat; validated, for IF / IP / IHC / Flow Cyt
155	rabbit monoclonal anti- ApoE (Clone EPR3326)	Abcam	ab215274	GR3309685-1	5	endogenous expression in Human, rat, mouse; KO validated for IP / WB
156	rabbit monoclonal anti- mouse iNOS (Clone D6B6S)	Cell Signaling Technologies	13120BF	6	10	endogenous expression in mouse; validated for IP / WB / IF / Flow Cyt
158	goat polyclonal anti- mouse IL33	R&D	AF3626	YJE0819121	3.3	endogenous expression in mouse; validated for ELISA / IP / Flow Cyt / IF / IHC
159	rabbit monoclonal anti- human PSD95 (Clone D74D3)	Cell Signaling Technologies	3409BF	5	4	endogenous expression in mouse, rat, human; validated for IHC / WB.
160	mouse monoclonal anti- human CD184 (Clone 12G5)	Biolegend	306523	B235925	8	endogenous expression in human; validated for Flow Cyt / IF / IHC. Used as negative control in mouse.
161	rabbit monoclonal anti- fibrinogen (Clone EPR18145-84)	Abcam	ab227063	GR3194483-1	10	endogenous expression in mouse, rat, human; validated for Flow Cyt / IHC.
162	rabbit monoclonal anti- human Tau (Clone D1M9X)	Cell Signaling Technologies	29384	2	3.3	endogenous expression in mouse, rat, human; KO validated for Flow Cyt / IHC / WB / IF.
163	rabbit monoclonal anti- EAAT2 (Clone EPR19798)	Abcam	271970	GR3340947-1	8	endogenous expression in mouse, rat, human; validated for IHC / WB / IP.
164	rabbit monoclonal anti- mouse CD68 (Clone E307V)	Cell Signaling Technologies	97778BF	2	8	endogenous expression in mouse; positive and negative control validated for IHC / IF / WB / Flow Cyt.
165	mouse monoclonal anti- mouse/rat MAP2 (Clone SMI 52)	Biolegend	801801	B266835	5	endogenous expression in mouse, rat; positive and negative control validated for ELISA / IHC / IF / WB / Flow Cyt.
166	rabbit monoclonal anti- beta-2 Microglobulin (Clone EPR21752-214)	Abcam	ab237032	GR3234347-2	7.5	endogenous expression in mouse, rat, human; KO validated for IHC / IP / WB / Flow Cyt.
167	rabbit monoclonal anti- Vascular Amyloid (Clone mOC31)	Abcam	ab251334	GR3336463-1	3	endogenous expression in mouse, human; validated for IHC.
168	mouse monoclonal anti- Ki67 (Clone B56)	FLUIDIGM	3168022D	2411806	2.5	endogenous expression in mouse, rat, human; KO validated for IF / IHC / Flow Cyt.
169	hamster monoclonal anti- mouse MCP1 (Clone 2H5)	Biolegend	505912	B296185	10	endogenous expression in mouse, rat, human; validated for WB / IHC / Flow Cyt / ELISA.
170	rabbit monoclonal anti- dopamine beta hydroxylase	Abcam	ab223130	GR3180359-1	4	endogenous expression in mouse, rat, human; validated for WB / IHC / IP.
171	rat monoclonal anti- mouse/human CD44 (Clone IM7)	Biolegend	103046	B338510		endogenous expression in mouse, human; validated for IHC / IP / IF.
172	rabbit polyclonal anti- human LINGO1	Sino Biological	101252-T08	HD10MA1826-B	3.5	endogenous expression in mouse, human; validated for IHC.
173	mouse monoclonal anti- gfap (Clone SMI 22)	Biolegend	835304	missing	0.8	endogenous expression in mouse, rat, human; validated for IHC / ICC / WB.
174	rabbit monoclonal anti- Iba (Clone EPR16589)	Abcam	ab221790	GR3347998-4	1.6	endogenous expression in mouse, rat, human; validated for IHC / ICC / WB.
175	rabbit monoclonal anti- NeuN (Clone EPR12763)	Abcam	ab209898	GR3271481-4	10	endogenous expression in mouse, rat, human; validated for IHC / ICC / IF / WB / Flow Cyt.
176	mouse monoclonal anti- CNPase (Clone SMI-91)	Biolegend	836404	missing	2.5	endogenous expression in mouse, rat, human; validated for IHC / ICC / IF / WB.
195	PM1	FLUIDIGM	TIS-00001 (ICSK1)	1742007	4	
196	PM2	FLUIDIGM	TIS-00001 (ICSK2)	1742008	4	endogenous expression in mouse, human; validated for IHC.
198	PM3	FLUIDIGM	TIS-00001 (ICSK3)	1882005	4	

904

905 Supplemental Table 3.


906

907 Subject Demographics

Demographics	Mean (SD), range
Age (years)	31.5 (9.4), 23–60
Education (years)	13.7 (1.5), 11–16
Race, nonwhite, <i>n</i> (%)	8 (24.2%)
<i>APOE</i> - ϵ 4-positive (%)	8 (25.8%)
Blast exposures	
Number of blast-related mild TBIs during military service (lifetime)	25.8 (24.2), 1–102, Median = 13
Number of lifetime mild TBIs with loss of consciousness	1.8 (1.8), 0–6, Median = 1
Time since last blast-related mild TBI (years)	3.6 (1.5), 1–7, Median = 4
Behavioral and neurological measures	
PCL-M score	40 (19.7), 17–79, Median = 34
PHQ-9 score	9.6 (7.4), 0–25
PSQI score	8.6 (5.8), 1–20;
AUDIT-C score	3.4 (2.7), 0–9
NSI total score	20.6 (17.8), 0–59, Median = 18
NSI+ total score	25.4 (21.7), 0–73, Median = 22

908

909 Supplemental Figure 1.
910




DNA and Cell membrane segmentation markers not shown

911
912
913 **Figure S1. T-SNE plots for separate IMC mass channels included in the study.**
914
915

916 Supplemental Figure 2.

917

918




919

920

921 **Figure S2. Average overpressure waveform for diffuse mTBI model.** Data represent the
922 average timestamped pressure measurements taken 5 cm above the animal over 102 trials
923 occurring over several days (red shown with black bars indicating \pm SEM). The blue line
924 represents the idealized Friedlander waveform produced by 11.35 kg of trinitrotoluene (TNT) at
925 a distance of 6.2 m.

926


927 Supplemental Figure 3.
928



929
930
931
932
933
934
935
936
937
938
939

Figure S3. Analysis of mRNA enrichment by RiboTag immunoprecipitation. (a-d) Real-time (RT) PCR amplification curves of (a) microglial Iba-1, (b) astrocytic GFAP, (c) neuronal NTRK2, and (d) the ubiquitous housekeeping gene GAPDH. Each curve represents either immunoprecipitated mRNA or input samples from individual mice. (e) Quantification of RT-PCR enrichment analyses using cortical hemisection tissue (N=4-8 per tissue). (f) Relative Iba-1 enrichment across brainstem (BS), cerebellum (CR), and cortical tissues (CTX) (N=2-6 per tissue).


940 Supplemental Figure 4.
941



942 **Figure S4. Locations used for confocal microscopy analyses of microglia internalization of**
943 **myelin CNPase.** Sagittal mouse brain section shows location of images taken from brainstem
944 pons, dorsal medulla (DM), and ventral white matter (VWM).
945
946

947
948 Supplemental Figure 5

949
950
951



952
953 **Figure S5. Sensitivity analyses for Pons FA mediation of cumulative blast exposure effects.**
954 **a)** Sensitivity analysis for mediated effects on TBI-associated neurobehavioral symptoms using
955 NSI+ total score. The results show that for the point estimate of the to be zero, the correlation of
956 ACME between the adjusted Pons FA value and PSQI total score must be approximately -0.9. **b)**
957 Sensitivity analysis for mediated effects on sleep using PSQI total score. The results show that
958 for the point estimate of the to be zero, the correlation of ACME between the adjusted Pons FA
959 value and PSQI total score must be approximately -0.4. Gray area is the 95% CI.
960

961 References

- 962
- 963 1. Dewan, M.C., *et al.* Estimating the global incidence of traumatic brain injury. *J*
 - 964 *Neurosurg*, 1-18 (2018).
 - 965 2. Renga, V. Clinical Evaluation and Treatment of Patients with Postconcussion Syndrome.
 - 966 *Neurol Res Int* **2021**, 5567695 (2021).
 - 967 3. Benusa, S.D. & Lafrenaye, A.D. Microglial process convergence on axonal segments in
 - 968 health and disease. *Neuroimmunol Neuroinflamm* **7**, 23-39 (2020).
 - 969 4. Eyolfson, E., Khan, A., Mychasiuk, R. & Lohman, A.W. Microglia dynamics in
 - 970 adolescent traumatic brain injury. *J Neuroinflammation* **17**, 326 (2020).
 - 971 5. Meaney, D.F., *et al.* Biomechanical analysis of experimental diffuse axonal injury. *J*
 - 972 *Neurotrauma* **12**, 689-694 (1995).
 - 973 6. Lippa, S.M., Pastorek, N.J., Benge, J.F. & Thornton, G.M. Postconcussive symptoms
 - 974 after blast and nonblast-related mild traumatic brain injuries in Afghanistan and Iraq war
 - 975 veterans. *J Int Neuropsychol Soc* **16**, 856-866 (2010).
 - 976 7. Mac Donald, C.L., *et al.* Prospectively assessed clinical outcomes in concussive blast vs
 - 977 nonblast traumatic brain injury among evacuated US military personnel. *JAMA Neurol*
 - 978 **71**, 994-1002 (2014).
 - 979 8. Cooper, D.B., Vanderploeg, R.D., Armistead-Jehle, P., Lewis, J.D. & Bowles, A.O.
 - 980 Factors associated with neurocognitive performance in OIF/OEF servicemembers with
 - 981 postconcussive complaints in postdeployment clinical settings. *J Rehabil Res Dev* **51**,
 - 982 1023-1034 (2014).
 - 983 9. Belanger, H.G., *et al.* Symptom complaints following reports of blast versus non-blast
 - 984 mild TBI: does mechanism of injury matter? *Clin Neuropsychol* **25**, 702-715 (2011).
 - 985 10. Cooper, D.B., *et al.* Association between combat stress and post-concussive symptom
 - 986 reporting in OEF/OIF service members with mild traumatic brain injuries. *Brain Inj* **25**,
 - 987 1-7 (2011).
 - 988 11. Belanger, H.G., Kretzmer, T., Yoash-Gantz, R., Pickett, T. & Tupler, L.A. Cognitive
 - 989 sequelae of blast-related versus other mechanisms of brain trauma. *J Int Neuropsychol*
 - 990 *Soc* **15**, 1-8 (2009).
 - 991 12. Huber, B.R., *et al.* Blast exposure causes early and persistent aberrant phospho- and
 - 992 cleaved-tau expression in a murine model of mild blast-induced traumatic brain injury. *J*
 - 993 *Alzheimers Dis* **37**, 309-323 (2013).
 - 994 13. McKee, A.C., Daneshvar, D.H., Alvarez, V.E. & Stein, T.D. The neuropathology of
 - 995 sport. *Acta Neuropathol* **127**, 29-51 (2014).
 - 996 14. Oppenheimer, D.R. Microscopic lesions in the brain following head injury. *J Neurol*
 - 997 *Neurosurg Psychiatry* **31**, 299-306 (1968).
 - 998 15. Korn, A., Golan, H., Melamed, I., Pascual-Marqui, R. & Friedman, A. Focal cortical
 - 999 dysfunction and blood-brain barrier disruption in patients with Postconcussion syndrome.
 - 1000 *J Clin Neurophysiol* **22**, 1-9 (2005).
 - 1001 16. Logsdon, A.F., *et al.* Blast exposure elicits blood-brain barrier disruption and repair
 - 1002 mediated by tight junction integrity and nitric oxide dependent processes. *Sci Rep* **8**,
 - 1003 11344 (2018).
 - 1004 17. Meabon, J.S., *et al.* Repetitive blast exposure in mice and combat veterans causes
 - 1005 persistent cerebellar dysfunction. *Sci Transl Med* **8**, 321ra326 (2016).

- 1006 18. Corsellis, J.A., Bruton, C.J. & Freeman-Browne, D. The aftermath of boxing. *Psychol*
1007 *Med* **3**, 270-303 (1973).
- 1008 19. Unterberg, A.W., Stover, J., Kress, B. & Kiening, K.L. Edema and brain trauma.
1009 *Neuroscience* **129**, 1021-1029 (2004).
- 1010 20. Kang, J.H. & Lin, H.C. Increased risk of multiple sclerosis after traumatic brain injury: a
1011 nationwide population-based study. *J Neurotrauma* **29**, 90-95 (2012).
- 1012 21. Lehman, E.J., Hein, M.J., Baron, S.L. & Gersic, C.M. Neurodegenerative causes of death
1013 among retired National Football League players. *Neurology* **79**, 1970-1974 (2012).
- 1014 22. Gardner, R.C., *et al.* Mild TBI and risk of Parkinson disease: A Chronic Effects of
1015 Neurotrauma Consortium Study. *Neurology* **90**, e1771-e1779 (2018).
- 1016 23. Keren-Shaul, H., *et al.* A Unique Microglia Type Associated with Restricting
1017 Development of Alzheimer's Disease. *Cell* **169**, 1276-1290 e1217 (2017).
- 1018 24. Haimon, Z., *et al.* Re-evaluating microglia expression profiles using RiboTag and cell
1019 isolation strategies. *Nat Immunol* **19**, 636-644 (2018).
- 1020 25. Mattei, D., *et al.* Enzymatic Dissociation Induces Transcriptional and Proteotype Bias in
1021 Brain Cell Populations. *Int J Mol Sci* **21**(2020).
- 1022 26. Olah, M., *et al.* Single cell RNA sequencing of human microglia uncovers a subset
1023 associated with Alzheimer's disease. *Nat Commun* **11**, 6129 (2020).
- 1024 27. Xu, J., *et al.* Multimodal single-cell/nucleus RNA sequencing data analysis uncovers
1025 molecular networks between disease-associated microglia and astrocytes with
1026 implications for drug repurposing in Alzheimer's disease. *Genome Res* **31**, 1900-1912
1027 (2021).
- 1028 28. Fu, R., Shen, Q., Xu, P., Luo, J.J. & Tang, Y. Phagocytosis of microglia in the central
1029 nervous system diseases. *Mol Neurobiol* **49**, 1422-1434 (2014).
- 1030 29. Trapp, B.D. & Nave, K.A. Multiple sclerosis: an immune or neurodegenerative disorder?
1031 *Annu Rev Neurosci* **31**, 247-269 (2008).
- 1032 30. Rasband, M.N., *et al.* CNP is required for maintenance of axon-glia interactions at nodes
1033 of Ranvier in the CNS. *Glia* **50**, 86-90 (2005).
- 1034 31. Singh, S., *et al.* Microglial nodules in early multiple sclerosis white matter are associated
1035 with degenerating axons. *Acta Neuropathol* **125**, 595-608 (2013).
- 1036 32. Viola-Saltzman, M. & Watson, N.F. Traumatic brain injury and sleep disorders. *Neurol*
1037 *Clin* **30**, 1299-1312 (2012).
- 1038 33. Mathias, J.L. & Alvaro, P.K. Prevalence of sleep disturbances, disorders, and problems
1039 following traumatic brain injury: a meta-analysis. *Sleep Med* **13**, 898-905 (2012).
- 1040 34. Ouellet, M.C., Beaulieu-Bonneau, S. & Morin, C.M. Insomnia in patients with traumatic
1041 brain injury: frequency, characteristics, and risk factors. *J Head Trauma Rehabil* **21**, 199-
1042 212 (2006).
- 1043 35. Collen, J., Orr, N., Lettieri, C.J., Carter, K. & Holley, A.B. Sleep disturbances among
1044 soldiers with combat-related traumatic brain injury. *Chest* **142**, 622-630 (2012).
- 1045 36. Clinchot, D.M., Bogner, J., Mysiw, W.J., Fugate, L. & Corrigan, J. Defining sleep
1046 disturbance after brain injury. *Am J Phys Med Rehabil* **77**, 291-295 (1998).
- 1047 37. Donohue, K.D., Medonza, D.C., Crane, E.R. & O'Hara, B.F. Assessment of a non-
1048 invasive high-throughput classifier for behaviours associated with sleep and wake in
1049 mice. *Biomed Eng Online* **7**, 14 (2008).
- 1050 38. Flores, A.E., *et al.* Pattern recognition of sleep in rodents using piezoelectric signals
1051 generated by gross body movements. *IEEE Trans Biomed Eng* **54**, 225-233 (2007).

- 1052 39. Rowe, R.K., *et al.* Diffuse brain injury induces acute post-traumatic sleep. *PLoS One* **9**,
1053 e82507 (2014).
- 1054 40. Liu, H., *et al.* Aging of cerebral white matter. *Ageing Res Rev* **34**, 64-76 (2017).
- 1055 41. Farrell-Carnahan, L., Franke, L., Graham, C. & McNamee, S. Subjective sleep
1056 disturbance in veterans receiving care in the Veterans Affairs Polytrauma System
1057 following blast-related mild traumatic brain injury. *Mil Med* **178**, 951-956 (2013).
- 1058 42. Norris, J.N., Sams, R., Lundblad, P., Frantz, E. & Harris, E. Blast-related mild traumatic
1059 brain injury in the acute phase: acute stress reactions partially mediate the relationship
1060 between loss of consciousness and symptoms. *Brain Inj* **28**, 1052-1062 (2014).
- 1061 43. Leng, Y., *et al.* Traumatic Brain Injury and Incidence Risk of Sleep Disorders in Nearly
1062 200,000 US Veterans. *Neurology* **96**, e1792-e1799 (2021).
- 1063 44. Meythaler, J.M., Peduzzi, J.D., Eleftheriou, E. & Novack, T.A. Current concepts: diffuse
1064 axonal injury-associated traumatic brain injury. *Arch Phys Med Rehabil* **82**, 1461-1471
1065 (2001).
- 1066 45. van Horssen, J., *et al.* Clusters of activated microglia in normal-appearing white matter
1067 show signs of innate immune activation. *J Neuroinflammation* **9**, 156 (2012).
- 1068 46. Aoun, R., Rawal, H., Attarian, H. & Sahni, A. Impact of traumatic brain injury on sleep:
1069 an overview. *Nat Sci Sleep* **11**, 131-140 (2019).
- 1070 47. Nassan, M. & Videnovic, A. Circadian rhythms in neurodegenerative disorders. *Nat Rev*
1071 *Neurol* **18**, 7-24 (2022).
- 1072 48. Schiff, N.D. Central thalamic contributions to arousal regulation and neurological
1073 disorders of consciousness. *Ann N Y Acad Sci* **1129**, 105-118 (2008).
- 1074 49. Edlow, B.L., *et al.* Neuroanatomic connectivity of the human ascending arousal system
1075 critical to consciousness and its disorders. *J Neuropathol Exp Neurol* **71**, 531-546 (2012).
- 1076 50. Schiff, N.D. Recovery of consciousness after brain injury: a mesocircuit hypothesis.
1077 *Trends Neurosci* **33**, 1-9 (2010).
- 1078 51. Steriade, M. Arousal: revisiting the reticular activating system. *Science* **272**, 225-226
1079 (1996).
- 1080 52. Moruzzi, G. & Magoun, H.W. Brain stem reticular formation and activation of the EEG.
1081 *Electroencephalogr Clin Neurophysiol* **1**, 455-473 (1949).
- 1082 53. Newman, D.B. & Ginsberg, C.Y. Brainstem reticular nuclei that project to the cerebellum
1083 in rats: a retrograde tracer study. *Brain Behav Evol* **39**, 24-68 (1992).
- 1084 54. Ryan, N.P., *et al.* White matter microstructure predicts longitudinal social cognitive
1085 outcomes after paediatric traumatic brain injury: a diffusion tensor imaging study.
1086 *Psychol Med* **48**, 679-691 (2018).
- 1087 55. Drijkoningen, D., *et al.* Regional volumes in brain stem and cerebellum are associated
1088 with postural impairments in young brain-injured patients. *Hum Brain Mapp* **36**, 4897-
1089 4909 (2015).
- 1090 56. De Andrés, I. & Reinoso-Suárez, F. Participation of the cerebellum in the regulation of
1091 the sleep-wakefulness cycle through the superior cerebellar peduncle. *Arch Ital Biol* **117**,
1092 140-163 (1979).
- 1093 57. Cunchillos, J.D. & De Andres, I. Participation of the cerebellum in the regulation of the
1094 sleep-wakefulness cycle. Results in cerebellectomized cats. *Electroencephalogr Clin*
1095 *Neurophysiol* **53**, 549-558 (1982).
- 1096 58. Boehme, N.A., *et al.* Axonopathy precedes cell death in ocular damage mediated by blast
1097 exposure. *Sci Rep* **11**, 11774 (2021).

- 1098 59. Perez-Garcia, G., *et al.* PTSD-Related Behavioral Traits in a Rat Model of Blast-Induced
1099 mTBI Are Reversed by the mGluR2/3 Receptor Antagonist BCI-838. *eNeuro* **5**(2018).
1100 60. Corrigan, F., *et al.* NK1 antagonists attenuate tau phosphorylation after blast and repeated
1101 concussive injury. *Sci Rep* **11**, 8861 (2021).
1102 61. Petrie, E.C., *et al.* Neuroimaging, behavioral, and psychological sequelae of repetitive
1103 combined blast/impact mild traumatic brain injury in Iraq and Afghanistan war veterans.
1104 *J Neurotrauma* **31**, 425-436 (2014).
1105 62. Goldstein, L.E., *et al.* Chronic traumatic encephalopathy in blast-exposed military
1106 veterans and a blast neurotrauma mouse model. *Sci Transl Med* **4**, 134ra160 (2012).
1107 63. Cernak, I., *et al.* The pathobiology of blast injuries and blast-induced neurotrauma as
1108 identified using a new experimental model of injury in mice. *Neurobiol Dis* **41**, 538-551
1109 (2011).
1110 64. Logsdon, A.F., *et al.* Nitric oxide synthase mediates cerebellar dysfunction in mice
1111 exposed to repetitive blast-induced mild traumatic brain injury. *Sci Rep* **10**, 9420 (2020).
1112 65. Yaghouby, F., Donohue, K.D., O'Hara, B.F. & Sunderam, S. Noninvasive dissection of
1113 mouse sleep using a piezoelectric motion sensor. *J Neurosci Methods* **259**, 90-100
1114 (2016).
1115 66. Mang, G.M., *et al.* Evaluation of a piezoelectric system as an alternative to
1116 electroencephalogram/ electromyogram recordings in mouse sleep studies. *Sleep* **37**,
1117 1383-1392 (2014).
1118 67. Giesen, C., *et al.* Highly multiplexed imaging of tumor tissues with subcellular resolution
1119 by mass cytometry. *Nat Methods* **11**, 417-422 (2014).
1120 68. Lein, E.S., *et al.* Genome-wide atlas of gene expression in the adult mouse brain. *Nature*
1121 **445**, 168-176 (2007).
1122 69. Schapiro, D., *et al.* histoCAT: analysis of cell phenotypes and interactions in multiplex
1123 image cytometry data. *Nat Methods* **14**, 873-876 (2017).
1124 70. Imai, K., Tingley, D. & Yamamoto, T. Experimental identification of causal mechanisms:
1125 Technical report Department of Politics, Princeton University (2009).
1126 71. Imai, K., Keele, L., Tingley, D. & Yamamoto, T. Causal mediation analysis using R. In
1127 *Advances in Social Science Research Using R*, Vol. 196, ed. Vinod, H. (Springer, New
1128 York, NY, 2010).
1129 72. Bittar, A., *et al.* Neurotoxic tau oligomers after single versus repetitive mild traumatic
1130 brain injury. *Brain Commun* **1**, fcz004 (2019).
1131